Scaling without slippage
Revenue up 54.0% YoY while gross margin expanded +259.9pp TTM to 340.1%
Frame pre-revenue biotech around cash runway, burn, and pipeline optionality instead of near-term profitability.
Pre-revenue biotech is not a margin story. It is a survival-and-optionality story shaped by cash runway, burn rate, R&D intensity, financing risk, and the value of future pipeline outcomes. The StatsAlpha(TM) biotech framework is designed to make that reality visible through runway-focused money flow, selective peer context, and a deliberately cautious analytical stance. It is for informational purposes only, not investment advice.
A quick read on where this framework looks strongest today.
Top slices selected from the strongest data already available for this industry.
Top 5 companies by current framework view
Recurring storylines, tone distribution, and representative beats pulled from active companies inside this setup.
Revenue up 54.0% YoY while gross margin expanded +259.9pp TTM to 340.1%
Revenue up 232.6% YoY while gross margin expanded +20.7pp TTM to 100.0%
Revenue up 30.2% YoY while gross margin expanded +26.1pp TTM to 97.9%
For informational purposes only. Not investment advice.
Metrics that recur most often across stronger operators in this framework.
Pre-Revenue Biotech
This framework softens or disables Profitability in the Trade-Off Ledger lens.
Each axis sets a minimum evidence threshold. Higher coverage means the framework needs more supporting signals before the lens is treated as dependable.
Coverage thresholds and enabled metrics across the core trade-off axes.
Median and interquartile range across 1022 companies in this framework.
Interquartile ranges show where the middle half of companies cluster, with the median pin marking the center of gravity for each pillar.
Scan the full company universe mapped into the Biotech / Pre-Revenue framework using live search across company name, ticker, and industry.
| Company | Market Cap | Score | Price | Strongest Pillar |
|---|---|---|---|---|
|
Biotechnology
|
118.47B
|
69.9
Composite
|
$466.79
|
Profitability
83.1
|
|
Biotechnology
|
64.21B
|
70.1
Composite
|
$612.50
|
Profitability
84.4
|
|
ARGX
argenx SE
Biotechnology
|
55.93B
|
68.4
Composite
|
$903.75
|
Profitability
86.3
|
|
Biotechnology
|
38.24B
|
77.0
Composite
|
$288.18
|
Valuation
92.3
|
|
Biotechnology
|
35.25B
|
47.0
Composite
|
$165.81
|
Efficiency
61.7
|
|
RPRX
Royalty Pharma plc
Biotechnology
|
30.85B
|
74.4
Composite
|
$53.57
|
Valuation
89.4
|
|
ONC
BeiGene, Ltd.
Biotechnology
|
30.21B
|
73.8
Composite
|
$271.80
|
Valuation
87.0
|
|
MRNA
Moderna, Inc.
Biotechnology
|
23.55B
|
49.0
Composite
|
$59.34
|
Profitability
67.3
|
|
Biotechnology
|
22.85B
|
69.5
Composite
|
$538.30
|
Profitability
86.2
|
|
BNTX
BioNTech SE
Biotechnology
|
22.81B
|
51.9
Composite
|
$90.19
|
Profitability
73.4
|
|
Biotechnology
|
22.61B
|
48.1
Composite
|
$31.25
|
Health
67.0
|
|
INSM
Insmed Incorporated
Biotechnology
|
20.76B
|
53.8
Composite
|
$98.61
|
Profitability
61.7
|
|
INCY
Incyte Corporation
Biotechnology
|
19.62B
|
74.2
Composite
|
$103.66
|
Profitability
86.6
|
|
GMAB
Genmab A/S
Biotechnology
|
16.45B
|
73.4
Composite
|
$25.61
|
Profitability
87.2
|
|
Biotechnology
|
14.17B
|
71.8
Composite
|
$225.92
|
Profitability
79.8
|
|
ASND
Ascendis Pharma A/S
Biotechnology
|
14.16B
|
61.1
Composite
|
$228.00
|
Profitability
76.5
|
|
Biotechnology
|
13.50B
|
54.1
Composite
|
$68.92
|
Profitability
68.8
|
|
EXEL
Exelixis, Inc.
Biotechnology
|
12.91B
|
72.5
Composite
|
$51.35
|
Profitability
86.4
|
|
Biotechnology
|
12.75B
|
61.5
Composite
|
$247.85
|
Health
72.6
|
|
Biotechnology
|
12.25B
|
53.6
Composite
|
$75.89
|
Profitability
64.9
|
|
Biotechnology
|
11.82B
|
63.5
Composite
|
$512.88
|
Profitability
77.2
|
|
Biotechnology
|
11.52B
|
74.7
Composite
|
$82.00
|
Valuation
91.3
|
|
Biotechnology
|
11.08B
|
53.8
Composite
|
$14.28
|
Profitability
61.3
|
|
Biotechnology
|
10.80B
|
68.1
Composite
|
$55.90
|
Profitability
82.3
|
|
Biotechnology
|
10.26B
|
76.4
Composite
|
$343.43
|
Valuation
88.4
|
|
Biotechnology
|
9.93B
|
54.1
Composite
|
$132.88
|
Efficiency
62.0
|
|
Biotechnology
|
9.85B
|
45.9
Composite
|
$79.17
|
Profitability
57.9
|
|
NUVL
Nuvalent, Inc.
Biotechnology
|
9.75B
|
64.8
Composite
|
$123.42
|
Profitability
75.6
|
|
Biotechnology
|
8.71B
|
58.8
Composite
|
$100.32
|
Profitability
68.7
|
|
TECH
Bio-Techne Corp
Biotechnology
|
8.71B
|
71.9
Composite
|
$55.61
|
Valuation
86.1
|
|
Biotechnology
|
8.56B
|
70.9
Composite
|
$79.71
|
Profitability
85.3
|
|
Biotechnology
|
8.33B
|
67.8
Composite
|
$54.40
|
Profitability
86.8
|
|
Biotechnology
|
8.18B
|
69.6
Composite
|
$68.99
|
Profitability
75.1
|
|
Biotechnology
|
8.18B
|
51.2
Composite
|
$99.45
|
Profitability
60.4
|
|
Biotechnology
|
7.87B
|
46.4
Composite
|
$303.39
|
Profitability
56.4
|
|
ABVX
Abivax SA
Biotechnology
|
7.83B
|
47.3
Composite
|
$98.43
|
Health
60.6
|
|
IBRX
ImmunityBio, Inc.
Biotechnology
|
7.56B
|
52.3
Composite
|
$7.22
|
Profitability
71.1
|
|
PCVX
Vaxcyte, Inc.
Biotechnology
|
7.52B
|
51.6
Composite
|
$52.11
|
Profitability
59.0
|
|
MTSR
Metsera, Inc.
Biotechnology
|
7.43B
|
0.0
Composite
|
$70.50
|
No pillar score
-
|
|
Biotechnology
|
7.40B
|
68.7
Composite
|
$115.03
|
Profitability
83.5
|
|
IMVT
Immunovant, Inc.
Biotechnology
|
7.26B
|
55.3
Composite
|
$38.10
|
Health
70.0
|
|
Biotechnology
|
6.95B
|
55.2
Composite
|
$101.39
|
Profitability
65.0
|
|
ACLX
Arcellx, Inc.
Biotechnology
|
6.75B
|
55.0
Composite
|
$115.07
|
Efficiency
68.8
|
|
Biotechnology
|
6.72B
|
61.4
Composite
|
$80.96
|
Profitability
72.7
|
|
LQDA
Liquidia Corporation
Biotechnology
|
6.71B
|
62.8
Composite
|
$75.49
|
Profitability
69.7
|
|
Biotechnology
|
6.53B
|
52.5
Composite
|
$107.77
|
Profitability
57.4
|
|
Biotechnology
|
6.22B
|
54.5
Composite
|
$40.18
|
Profitability
59.2
|
|
Biotechnology
|
6.13B
|
54.7
Composite
|
$35.84
|
Profitability
58.2
|
|
Biotechnology
|
6.11B
|
56.1
Composite
|
$52.95
|
Health
67.9
|
|
Biotechnology
|
5.89B
|
52.4
Composite
|
$49.19
|
Health
57.9
|
|
CGON
CG Oncology, Inc.
Biotechnology
|
5.84B
|
54.7
Composite
|
$66.25
|
Efficiency
58.8
|
|
BLTE
Belite Bio, Inc
Biotechnology
|
5.79B
|
55.5
Composite
|
$147.07
|
Profitability
75.7
|
|
Biotechnology
|
5.51B
|
74.0
Composite
|
$262.17
|
Profitability
82.6
|
|
Biotechnology
|
5.45B
|
59.1
Composite
|
$29.34
|
Profitability
70.3
|
|
Biotechnology
|
5.30B
|
51.3
Composite
|
$54.79
|
Health
69.6
|
|
Biotechnology
|
5.25B
|
65.2
Composite
|
$41.03
|
Profitability
78.4
|
|
Biotechnology
|
5.24B
|
55.1
Composite
|
$54.36
|
Profitability
70.8
|
|
ORKA
ARCA biopharma Inc
Biotechnology
|
5.15B
|
54.5
Composite
|
$85.38
|
Growth
60.8
|
|
Biotechnology
|
5.12B
|
68.2
Composite
|
$55.11
|
Profitability
78.0
|
|
Biotechnology
|
4.78B
|
50.2
Composite
|
$87.37
|
Health
66.8
|
|
ERAS
Erasca, Inc.
Biotechnology
|
4.69B
|
56.2
Composite
|
$15.08
|
Profitability
62.7
|
|
Biotechnology
|
4.55B
|
68.1
Composite
|
$14.49
|
Profitability
78.9
|
|
CELC
Celcuity Inc.
Biotechnology
|
4.39B
|
46.3
Composite
|
$89.93
|
Health
61.9
|
|
Biotechnology
|
4.12B
|
58.0
Composite
|
$28.50
|
Profitability
71.0
|
|
Biotechnology
|
3.96B
|
52.7
Composite
|
$36.50
|
Health
61.5
|
|
Biotechnology
|
3.84B
|
71.7
Composite
|
$31.38
|
Profitability
85.6
|
|
Biotechnology
|
3.78B
|
70.9
Composite
|
$22.60
|
Profitability
86.0
|
|
Biotechnology
|
3.78B
|
48.0
Composite
|
$35.38
|
Efficiency
57.4
|
|
Biotechnology
|
3.77B
|
54.0
Composite
|
$17.28
|
Health
57.7
|
|
Biotechnology
|
3.76B
|
45.2
Composite
|
$32.37
|
Efficiency
67.1
|
|
Biotechnology
|
3.70B
|
56.8
Composite
|
$24.05
|
Profitability
69.1
|
|
Biotechnology
|
3.60B
|
49.6
Composite
|
$30.82
|
Health
55.5
|
|
Biotechnology
|
3.54B
|
65.8
Composite
|
$35.53
|
Profitability
81.5
|
|
Biotechnology
|
3.45B
|
53.0
Composite
|
$20.87
|
Efficiency
54.6
|
|
Biotechnology
|
3.42B
|
54.7
Composite
|
$27.23
|
Profitability
68.2
|
|
Biotechnology
|
3.38B
|
68.3
Composite
|
$10.00
|
Profitability
81.1
|
|
Biotechnology
|
3.33B
|
69.2
Composite
|
$26.66
|
Profitability
82.0
|
|
Biotechnology
|
3.23B
|
57.3
Composite
|
$45.51
|
Health
69.1
|
|
Biotechnology
|
3.01B
|
63.8
Composite
|
$34.23
|
Profitability
73.7
|
|
ALMS
Alumis Inc.
Biotechnology
|
2.98B
|
46.0
Composite
|
$24.51
|
Growth
52.2
|
|
QURE
uniQure N.V.
Biotechnology
|
2.92B
|
51.6
Composite
|
$44.39
|
Health
65.1
|
|
Biotechnology
|
2.80B
|
53.0
Composite
|
$45.96
|
Health
67.2
|
|
Biotechnology
|
2.78B
|
65.3
Composite
|
$17.23
|
Profitability
78.1
|
|
Biotechnology
|
2.76B
|
74.2
Composite
|
$53.01
|
Valuation
85.9
|
|
Biotechnology
|
2.76B
|
53.3
Composite
|
$38.43
|
Profitability
63.8
|
|
Biotechnology
|
2.73B
|
69.8
Composite
|
$63.56
|
Profitability
81.9
|
|
IRON
Disc Medicine, Inc.
Biotechnology
|
2.70B
|
55.7
Composite
|
$70.80
|
Profitability
72.2
|
|
Biotechnology
|
2.70B
|
53.8
Composite
|
$29.03
|
Health
58.1
|
|
Biotechnology
|
2.55B
|
47.0
Composite
|
$33.41
|
Health
57.4
|
|
Biotechnology
|
2.44B
|
49.0
Composite
|
$17.71
|
Growth
65.0
|
|
BHVN
Biohaven Ltd.
Biotechnology
|
2.33B
|
47.9
Composite
|
$15.50
|
Health
55.2
|
|
Biotechnology
|
2.32B
|
70.0
Composite
|
$9.14
|
Profitability
76.5
|
|
PHVS
Pharvaris N.V.
Biotechnology
|
2.31B
|
47.6
Composite
|
$33.00
|
Profitability
55.6
|
|
Biotechnology
|
2.29B
|
40.8
Composite
|
$36.63
|
Valuation
48.1
|
|
Biotechnology
|
2.25B
|
72.8
Composite
|
$17.53
|
Profitability
85.2
|
|
Biotechnology
|
2.22B
|
62.0
Composite
|
$21.53
|
Profitability
76.3
|
|
NKTR
Nektar Therapeutics
Biotechnology
|
2.22B
|
47.6
Composite
|
$65.70
|
Health
58.5
|
|
Biotechnology
|
2.19B
|
54.1
Composite
|
$15.75
|
Profitability
64.7
|
|
IMNM
Immunome, Inc.
Biotechnology
|
2.17B
|
55.0
Composite
|
$19.18
|
Efficiency
68.3
|
|
Biotechnology
|
2.09B
|
58.8
Composite
|
$25.37
|
Health
68.9
|
|
Biotechnology
|
2.09B
|
60.1
Composite
|
$43.91
|
Profitability
67.3
|
|
Biotechnology
|
2.09B
|
51.7
Composite
|
$35.59
|
Profitability
61.5
|
|
Biotechnology
|
2.06B
|
56.3
Composite
|
$9.97
|
Health
66.0
|
|
VCEL
Vericel Corporation
Biotechnology
|
2.05B
|
73.5
Composite
|
$40.47
|
Valuation
86.1
|
|
ZLAB
Zai Lab Limited
Biotechnology
|
2.04B
|
57.9
Composite
|
$18.48
|
Profitability
74.7
|
|
NUVB
Nuvation Bio Inc.
Biotechnology
|
2.01B
|
59.5
Composite
|
$5.76
|
Profitability
65.6
|
|
MESO
Mesoblast Limited
Biotechnology
|
2.00B
|
55.7
Composite
|
$15.50
|
Profitability
69.2
|
|
ADMA
ADMA Biologics Inc
Biotechnology
|
1.99B
|
65.0
Composite
|
$8.69
|
Profitability
83.8
|
|
Biotechnology
|
1.94B
|
72.5
Composite
|
$33.43
|
Profitability
84.2
|
|
Biotechnology
|
1.93B
|
68.9
Composite
|
$30.97
|
Profitability
82.3
|
|
Biotechnology
|
1.88B
|
54.0
Composite
|
$6.53
|
Profitability
59.6
|
|
GLPG
Galapagos NV
Biotechnology
|
1.87B
|
65.1
Composite
|
$28.37
|
Profitability
82.5
|
|
Biotechnology
|
1.86B
|
56.0
Composite
|
$17.65
|
Profitability
65.8
|
|
Biotechnology
|
1.83B
|
56.1
Composite
|
$38.19
|
Profitability
64.9
|
|
Biotechnology
|
1.82B
|
52.4
Composite
|
$17.63
|
Health
62.5
|
|
Biotechnology
|
1.81B
|
50.5
Composite
|
$18.65
|
Profitability
58.6
|
|
Biotechnology
|
1.81B
|
59.5
Composite
|
$4.06
|
Profitability
71.6
|
|
Biotechnology
|
1.81B
|
54.5
Composite
|
$16.37
|
Profitability
62.2
|
|
Biotechnology
|
1.79B
|
59.1
Composite
|
$58.01
|
Profitability
75.8
|
|
Biotechnology
|
1.79B
|
48.3
Composite
|
$30.14
|
Efficiency
56.5
|
|
NBTX
Nanobiotix S.A.
Biotechnology
|
1.76B
|
49.1
Composite
|
$35.23
|
Profitability
64.8
|
|
Biotechnology
|
1.75B
|
52.6
Composite
|
$38.83
|
Profitability
62.4
|
|
Biotechnology
|
1.75B
|
57.4
Composite
|
$5.63
|
Profitability
74.2
|
|
Biotechnology
|
1.75B
|
50.5
Composite
|
$18.09
|
Efficiency
85.4
|
|
ANAB
AnaptysBio, Inc.
Biotechnology
|
1.75B
|
65.6
Composite
|
$59.43
|
Profitability
78.5
|
|
PGEN
Precigen, Inc.
Biotechnology
|
1.72B
|
39.1
Composite
|
$5.38
|
Health
62.1
|
|
Biotechnology
|
1.71B
|
54.8
Composite
|
$19.32
|
Profitability
65.9
|
|
URGN
UroGen Pharma Ltd.
Biotechnology
|
1.70B
|
47.4
Composite
|
$34.99
|
Profitability
57.6
|
|
Biotechnology
|
1.70B
|
48.2
Composite
|
$118.84
|
Health
53.9
|
|
Biotechnology
|
1.70B
|
57.7
Composite
|
$29.34
|
Profitability
77.1
|
|
ZYME
Zymeworks Inc.
Biotechnology
|
1.70B
|
56.5
Composite
|
$23.26
|
Profitability
75.0
|
|
Biotechnology
|
1.69B
|
53.1
Composite
|
$3.18
|
Profitability
62.2
|
|
Shell Companies
|
1.67B
|
56.8
Composite
|
$18.83
|
Growth
84.8
|
|
INVA
Innoviva, Inc.
Biotechnology
|
1.66B
|
74.4
Composite
|
$22.67
|
Profitability
83.3
|
|
Biotechnology
|
1.63B
|
48.6
Composite
|
$22.16
|
Valuation
61.3
|
|
Biotechnology
|
1.61B
|
46.3
Composite
|
$9.57
|
Profitability
65.2
|
|
Biotechnology
|
1.61B
|
49.9
Composite
|
$24.55
|
Profitability
64.6
|
|
Biotechnology
|
1.58B
|
58.8
Composite
|
$18.67
|
Profitability
75.7
|
|
ARDX
Ardelyx, Inc.
Biotechnology
|
1.57B
|
64.5
Composite
|
$6.37
|
Profitability
78.8
|
|
SEPN
Septerna, Inc.
Biotechnology
|
1.57B
|
67.8
Composite
|
$34.85
|
Profitability
79.2
|
|
Biotechnology
|
1.52B
|
65.3
Composite
|
$32.70
|
Profitability
80.0
|
|
GHRS
GH Research PLC
Biotechnology
|
1.52B
|
51.4
Composite
|
$22.09
|
Profitability
71.5
|
|
Biotechnology
|
1.50B
|
57.9
Composite
|
$8.53
|
Profitability
60.5
|
|
Biotechnology
|
1.49B
|
41.9
Composite
|
$4.05
|
Valuation
56.5
|
|
GLTO
Galecto, Inc.
Biotechnology
|
1.49B
|
56.0
Composite
|
$24.99
|
Valuation
66.7
|
|
NVAX
Novavax, Inc.
Biotechnology
|
1.48B
|
56.3
Composite
|
$9.00
|
Profitability
73.1
|
|
Biotechnology
|
1.48B
|
72.9
Composite
|
$17.01
|
Growth
86.1
|
|
Biotechnology
|
1.45B
|
56.2
Composite
|
$29.35
|
Profitability
78.2
|
|
Biotechnology
|
1.45B
|
63.1
Composite
|
$15.56
|
Profitability
71.7
|
|
Biotechnology
|
1.44B
|
50.4
Composite
|
$27.00
|
Health
61.8
|
|
Biotechnology
|
1.42B
|
58.3
Composite
|
$25.57
|
Profitability
69.8
|
|
Biotechnology
|
1.37B
|
39.6
Composite
|
$93.30
|
Health
58.0
|
|
Biotechnology
|
1.36B
|
58.1
Composite
|
$5.25
|
Profitability
68.0
|
|
IMTX
Immatics N.V.
Biotechnology
|
1.34B
|
51.5
Composite
|
$9.78
|
Profitability
66.0
|
|
Biotechnology
|
1.31B
|
45.9
Composite
|
$20.80
|
Efficiency
60.2
|
|
MNKD
MannKind Corporation
Biotechnology
|
1.20B
|
64.7
Composite
|
$3.89
|
Profitability
82.0
|
|
Biotechnology
|
1.19B
|
69.9
Composite
|
$6.90
|
Profitability
79.1
|
|
Biotechnology
|
1.19B
|
57.8
Composite
|
$6.17
|
Profitability
70.3
|
|
SVRA
Savara, Inc.
Biotechnology
|
1.17B
|
53.7
Composite
|
$5.69
|
Health
61.9
|
|
ABSI
Absci Corporation
Biotechnology
|
1.16B
|
43.9
Composite
|
$7.41
|
Efficiency
57.5
|
|
Biotechnology
|
1.15B
|
47.6
Composite
|
$13.73
|
Profitability
58.3
|
|
Shell Companies
|
1.08B
|
50.6
Composite
|
$22.57
|
Valuation
59.5
|
|
Biotechnology
|
1.06B
|
51.5
Composite
|
$17.30
|
Health
61.2
|
|
Biotechnology
|
1.06B
|
46.9
Composite
|
$11.48
|
Profitability
57.2
|
|
CVAC
CureVac N.V.
Biotechnology
|
1.05B
|
69.9
Composite
|
$4.66
|
Profitability
85.9
|
|
XNCR
Xencor, Inc.
Biotechnology
|
1.04B
|
62.7
Composite
|
$14.01
|
Profitability
75.8
|
|
Biotechnology
|
1.01B
|
48.0
Composite
|
$3.36
|
Health
62.4
|
|
Biotechnology
|
1.00B
|
51.8
Composite
|
$14.00
|
Valuation
57.0
|
|
Biotechnology
|
1.00B
|
54.2
Composite
|
$12.56
|
Growth
70.6
|
|
Biotechnology
|
991.54M
|
52.5
Composite
|
$9.98
|
Profitability
61.6
|
|
Shell Companies
|
937.42M
|
50.0
Composite
|
$5.33
|
Growth
86.2
|
|
Biotechnology
|
924.41M
|
57.4
Composite
|
$8.93
|
Growth
61.5
|
|
Biotechnology
|
923.16M
|
52.2
Composite
|
$11.18
|
Profitability
58.8
|
|
KURA
Kura Oncology, Inc.
Biotechnology
|
919.70M
|
52.4
Composite
|
$10.36
|
Profitability
59.4
|
|
Biotechnology
|
919.50M
|
46.2
Composite
|
$15.70
|
Health
56.1
|
|
PHAR
Pharming Group N.V.
Biotechnology
|
917.37M
|
69.5
Composite
|
$12.71
|
Profitability
81.4
|
|
Biotechnology
|
904.47M
|
54.0
Composite
|
$10.03
|
Efficiency
69.5
|
|
Biotechnology
|
897.80M
|
44.4
Composite
|
$17.08
|
Valuation
55.3
|
|
Biotechnology
|
892.90M
|
52.9
Composite
|
$4.45
|
Profitability
72.8
|
|
Biotechnology
|
892.80M
|
61.2
Composite
|
$2.15
|
Profitability
70.4
|
|
Biotechnology
|
874.52M
|
61.4
Composite
|
$14.34
|
Profitability
78.8
|
|
Biotechnology
|
873.47M
|
55.2
Composite
|
$10.00
|
Health
62.1
|
|
GERN
Geron Corporation
Biotechnology
|
859.60M
|
60.3
Composite
|
$1.34
|
Profitability
72.1
|
|
Biotechnology
|
855.66M
|
54.2
Composite
|
$13.70
|
Profitability
60.5
|
|
Biotechnology
|
853.70M
|
71.4
Composite
|
$16.56
|
Profitability
84.0
|
|
Biotechnology
|
849.11M
|
53.3
Composite
|
$10.69
|
Profitability
69.9
|
|
ANNX
Annexon, Inc.
Biotechnology
|
825.77M
|
53.0
Composite
|
$5.28
|
Valuation
60.2
|
|
Biotechnology
|
817.10M
|
47.4
Composite
|
$8.30
|
Profitability
56.8
|
|
Biotechnology
|
809.54M
|
49.6
Composite
|
$14.94
|
Profitability
61.5
|
|
Biotechnology
|
804.70M
|
53.7
Composite
|
$24.44
|
Valuation
63.4
|
|
Biotechnology
|
747.80M
|
61.6
Composite
|
$12.65
|
Profitability
82.4
|
|
OMER
Omeros Corporation
Biotechnology
|
747.60M
|
43.9
Composite
|
$10.33
|
Growth
55.9
|
|
Biotechnology
|
724.82M
|
43.0
Composite
|
$2.07
|
Valuation
61.0
|
|
Biotechnology
|
722.70M
|
55.7
Composite
|
$6.89
|
Valuation
66.6
|
|
Biotechnology
|
718.10M
|
50.2
Composite
|
$12.58
|
Valuation
52.0
|
|
Biotechnology
|
714.31M
|
37.4
Composite
|
$3.51
|
Health
46.6
|
|
Shell Companies
|
705.82M
|
44.4
Composite
|
$11.41
|
Profitability
57.0
|
|
Biotechnology
|
699.30M
|
53.4
Composite
|
$6.95
|
Valuation
57.7
|
|
CLYM
Climb Bio, Inc.
Biotechnology
|
697.43M
|
55.4
Composite
|
$12.18
|
Profitability
70.2
|
|
CRMD
CorMedix Inc.
Biotechnology
|
691.90M
|
77.4
Composite
|
$8.82
|
Profitability
87.4
|
|
Biotechnology
|
677.55M
|
47.0
Composite
|
$11.67
|
Efficiency
63.0
|
|
Biotechnology
|
661.80M
|
55.9
Composite
|
$3.04
|
Profitability
77.6
|
|
Biotechnology
|
661.10M
|
73.6
Composite
|
$35.73
|
Profitability
86.2
|
|
Biotechnology
|
625.87M
|
45.7
Composite
|
$12.25
|
Valuation
48.2
|
|
Biotechnology
|
620.78M
|
51.1
Composite
|
$9.40
|
Growth
62.7
|
|
Biotechnology
|
618.56M
|
54.8
Composite
|
$63.49
|
Profitability
83.0
|
|
Biotechnology
|
608.88M
|
57.6
Composite
|
$9.15
|
Profitability
66.5
|
|
PRME
Prime Medicine, Inc.
Biotechnology
|
608.68M
|
43.3
Composite
|
$3.37
|
Valuation
61.2
|
|
Biotechnology
|
590.53M
|
46.8
Composite
|
$9.04
|
Profitability
62.9
|
|
Biotechnology
|
572.49M
|
54.9
Composite
|
$30.34
|
Profitability
66.6
|
|
ALT
Altimmune, Inc.
Biotechnology
|
569.81M
|
50.1
Composite
|
$2.91
|
Health
57.9
|
|
Biotechnology
|
560.11M
|
67.0
Composite
|
$6.13
|
Profitability
84.6
|
|
PROK
ProKidney Corp.
Biotechnology
|
549.70M
|
48.3
Composite
|
$1.82
|
Efficiency
65.7
|
|
MDXG
MiMedx Group, Inc
Biotechnology
|
546.60M
|
71.8
Composite
|
$3.67
|
Profitability
84.5
|
|
Biotechnology
|
526.70M
|
72.5
Composite
|
$42.00
|
Profitability
82.4
|
|
Biotechnology
|
522.80M
|
45.5
Composite
|
$31.55
|
Profitability
62.9
|
|
NGNE
Neurogene Inc.
Biotechnology
|
509.61M
|
44.0
Composite
|
$32.25
|
Valuation
55.9
|
|
Biotechnology
|
504.99M
|
58.4
Composite
|
$10.42
|
Profitability
65.7
|
|
VALN
Valneva SE
Biotechnology
|
500.27M
|
51.9
Composite
|
$5.35
|
Profitability
64.0
|
|
ARVN
Arvinas, Inc.
Biotechnology
|
499.39M
|
52.5
Composite
|
$7.74
|
Profitability
71.4
|
|
Biotechnology
|
497.90M
|
55.7
Composite
|
$5.01
|
Profitability
66.6
|
|
RZLT
Rezolute, Inc.
Biotechnology
|
495.90M
|
60.5
Composite
|
$5.15
|
Profitability
75.7
|
|
CABA
Cabaletta Bio, Inc.
Biotechnology
|
490.79M
|
50.6
Composite
|
$3.01
|
Health
60.5
|
|
Biotechnology
|
490.62M
|
49.4
Composite
|
$8.30
|
Valuation
57.1
|
|
Biotechnology
|
479.00M
|
45.9
Composite
|
$9.15
|
Valuation
64.0
|
|
Shell Companies
|
473.64M
|
56.8
Composite
|
$11.40
|
Valuation
71.6
|
|
Biotechnology
|
455.54M
|
55.6
Composite
|
$4.12
|
Profitability
73.6
|
|
Biotechnology
|
454.79M
|
44.0
Composite
|
$9.36
|
Valuation
62.7
|
|
Biotechnology
|
451.97M
|
63.1
Composite
|
$68.66
|
Growth
84.6
|
|
Biotechnology
|
446.68M
|
46.3
Composite
|
$18.28
|
Health
57.6
|
|
Biotechnology
|
446.39M
|
60.2
Composite
|
$11.62
|
Profitability
77.0
|
|
Biotechnology
|
438.47M
|
67.5
Composite
|
$16.53
|
Profitability
79.0
|
|
Biotechnology
|
438.44M
|
57.8
Composite
|
$7.10
|
Profitability
68.4
|
|
OCGN
Ocugen, Inc.
Biotechnology
|
436.69M
|
43.9
Composite
|
$1.29
|
Health
49.9
|
|
Biotechnology
|
429.69M
|
47.6
Composite
|
$2.80
|
Valuation
55.9
|
|
Biotechnology
|
428.45M
|
51.2
Composite
|
$4.32
|
Health
57.6
|
|
Biotechnology
|
427.49M
|
45.5
Composite
|
$3.77
|
Health
63.9
|
|
PRTC
PureTech Health plc
Biotechnology
|
423.21M
|
43.9
Composite
|
$17.34
|
Health
50.8
|
|
Biotechnology
|
422.56M
|
51.9
Composite
|
$12.30
|
Health
62.5
|
|
Biotechnology
|
420.92M
|
48.1
Composite
|
$33.92
|
Valuation
52.4
|
|
Biotechnology
|
419.90M
|
58.5
Composite
|
$2.25
|
Profitability
73.8
|
|
Biotechnology
|
416.00M
|
42.6
Composite
|
$10.60
|
Profitability
49.9
|
|
Biotechnology
|
413.01M
|
63.1
Composite
|
$2.30
|
Profitability
77.7
|
|
RGNX
REGENXBIO Inc.
Biotechnology
|
403.20M
|
55.9
Composite
|
$9.07
|
Health
62.3
|
|
Biotechnology
|
401.90M
|
51.9
Composite
|
$1.49
|
Profitability
54.0
|
|
STTK
Shattuck Labs, Inc.
Biotechnology
|
401.81M
|
49.8
Composite
|
$5.24
|
Health
56.2
|
|
Biotechnology
|
399.70M
|
65.0
Composite
|
$25.15
|
Profitability
80.1
|
|
Shell Companies
|
397.05M
|
49.6
Composite
|
$10.83
|
Profitability
59.0
|
|
Biotechnology
|
395.75M
|
45.7
Composite
|
$5.04
|
Growth
57.9
|
|
Shell Companies
|
391.72M
|
44.7
Composite
|
$10.80
|
Efficiency
60.9
|
|
Shell Companies
|
391.72M
|
52.8
Composite
|
$10.90
|
Profitability
66.7
|
|
Biotechnology
|
389.90M
|
72.3
Composite
|
$7.66
|
Profitability
82.9
|
|
Biotechnology
|
388.80M
|
62.1
Composite
|
$13.37
|
Profitability
78.0
|
|
Biotechnology
|
388.60M
|
55.9
Composite
|
$4.12
|
Growth
69.2
|
|
Shell Companies
|
388.12M
|
55.5
Composite
|
$10.80
|
Profitability
64.0
|
|
Biotechnology
|
382.04M
|
52.0
Composite
|
$3.66
|
Health
67.2
|
|
VSTM
Verastem, Inc.
Biotechnology
|
373.50M
|
48.1
Composite
|
$4.25
|
Growth
55.1
|
|
Biotechnology
|
365.80M
|
49.6
Composite
|
$3.46
|
Profitability
60.6
|
|
Biotechnology
|
363.78M
|
50.3
Composite
|
$2.10
|
Health
58.7
|
|
Biotechnology
|
360.80M
|
55.4
Composite
|
$6.00
|
Profitability
68.1
|
|
ZURA
Zura Bio Limited
Biotechnology
|
356.24M
|
49.8
Composite
|
$4.23
|
Profitability
62.1
|
|
Biotechnology
|
355.67M
|
40.2
Composite
|
$7.53
|
Valuation
60.6
|
|
Biotechnology
|
351.32M
|
56.0
Composite
|
$4.39
|
Efficiency
92.3
|
|
Biotechnology
|
348.61M
|
40.7
Composite
|
$23.75
|
Health
59.4
|
|
Shell Companies
|
345.25M
|
45.6
Composite
|
$11.00
|
Growth
81.7
|
|
Biotechnology
|
342.85M
|
47.1
Composite
|
$6.30
|
Valuation
55.4
|
|
OABI
OmniAb, Inc.
Biotechnology
|
336.34M
|
55.3
Composite
|
$2.32
|
Profitability
70.5
|
|
Shell Companies
|
333.22M
|
58.4
Composite
|
$10.64
|
Growth
84.4
|
|
Biotechnology
|
331.28M
|
49.8
Composite
|
$4.08
|
Health
60.6
|
|
Shell Companies
|
331.20M
|
47.4
Composite
|
$10.80
|
Profitability
65.1
|
|
Biotechnology
|
331.00M
|
56.4
Composite
|
$9.53
|
Profitability
75.7
|
|
Shell Companies
|
330.00M
|
50.4
Composite
|
$10.75
|
Profitability
58.6
|
|
Biotechnology
|
327.70M
|
67.0
Composite
|
$5.72
|
Growth
78.8
|
|
Shell Companies
|
322.92M
|
53.0
Composite
|
$10.53
|
Growth
82.5
|
|
PALI
Palisade Bio, Inc.
Biotechnology
|
319.39M
|
55.3
Composite
|
$1.84
|
Growth
72.7
|
|
Shell Companies
|
318.99M
|
63.1
Composite
|
$10.68
|
Efficiency
77.6
|
|
Biotechnology
|
318.07M
|
44.0
Composite
|
$0.19
|
Efficiency
63.5
|
|
Shell Companies
|
317.23M
|
52.3
Composite
|
$10.75
|
Growth
80.6
|
|
Biotechnology
|
315.20M
|
56.0
Composite
|
$5.89
|
Profitability
74.5
|
|
Shell Companies
|
315.13M
|
56.8
Composite
|
$10.65
|
Growth
77.9
|
|
Biotechnology
|
314.10M
|
54.1
Composite
|
$1.26
|
Profitability
76.8
|
|
Biotechnology
|
313.58M
|
52.9
Composite
|
$1.84
|
Growth
62.2
|
|
Shell Companies
|
311.36M
|
56.1
Composite
|
$10.83
|
Profitability
75.8
|
|
GRAF
Graf Global Corp.
Shell Companies
|
310.50M
|
49.6
Composite
|
$10.86
|
Profitability
67.4
|
|
Shell Companies
|
308.64M
|
52.6
Composite
|
$10.61
|
Growth
100.0
|
|
Shell Companies
|
307.34M
|
55.2
Composite
|
$10.69
|
Growth
77.8
|
|
Biotechnology
|
305.86M
|
54.3
Composite
|
$3.93
|
Growth
71.2
|
|
Biotechnology
|
294.52M
|
50.5
Composite
|
$3.81
|
Growth
67.8
|
|
Biotechnology
|
293.55M
|
55.2
Composite
|
$2.31
|
Profitability
69.8
|
|
Biotechnology
|
292.35M
|
41.0
Composite
|
$9.95
|
Valuation
51.9
|
|
MGNX
MacroGenics, Inc.
Biotechnology
|
291.10M
|
50.2
Composite
|
$4.58
|
Profitability
61.0
|
|
Biotechnology
|
287.26M
|
59.5
Composite
|
$4.44
|
Profitability
72.0
|
|
Shell Companies
|
286.67M
|
49.1
Composite
|
$11.05
|
Profitability
65.1
|
|
IVVD
Invivyd, Inc.
Biotechnology
|
285.74M
|
64.5
Composite
|
$0.91
|
Profitability
75.6
|
|
Biotechnology
|
283.48M
|
48.2
Composite
|
$1.53
|
Valuation
59.9
|
|
Shell Companies
|
281.87M
|
56.5
Composite
|
$10.58
|
Growth
82.5
|
|
IFRX
InflaRx N.V.
Biotechnology
|
279.86M
|
41.0
Composite
|
$1.90
|
Valuation
62.1
|
|
Biotechnology
|
279.31M
|
44.5
Composite
|
$11.97
|
Valuation
62.7
|
|
Biotechnology
|
277.85M
|
51.8
Composite
|
$3.98
|
Profitability
66.5
|
|
SBXD
SilverBox Corp IV
Shell Companies
|
275.68M
|
49.0
Composite
|
$10.83
|
Profitability
63.1
|
|
Shell Companies
|
274.56M
|
57.5
Composite
|
$10.60
|
Growth
100.0
|
|
Shell Companies
|
273.99M
|
54.8
Composite
|
$9.52
|
Profitability
71.6
|
|
Shell Companies
|
271.68M
|
52.9
Composite
|
$10.44
|
Growth
100.0
|
|
Shell Companies
|
271.31M
|
54.1
Composite
|
$11.04
|
Profitability
77.0
|
|
Shell Companies
|
271.06M
|
48.8
Composite
|
$10.63
|
Efficiency
56.3
|
|
Shell Companies
|
270.00M
|
55.6
Composite
|
$11.00
|
Growth
71.4
|
|
SRZN
Surrozen, Inc.
Biotechnology
|
269.94M
|
38.7
Composite
|
$23.66
|
Valuation
43.0
|
|
Shell Companies
|
269.37M
|
46.7
Composite
|
$10.68
|
Growth
100.0
|
|
Shell Companies
|
261.81M
|
58.0
Composite
|
$10.65
|
Profitability
69.7
|
|
Biotechnology
|
261.25M
|
51.7
Composite
|
$3.67
|
Profitability
60.6
|
|
Shell Companies
|
259.26M
|
55.5
Composite
|
$7.68
|
Growth
77.2
|
|
Shell Companies
|
257.70M
|
59.4
Composite
|
$10.63
|
Growth
100.0
|
|
Shell Companies
|
256.36M
|
59.5
Composite
|
$10.63
|
Growth
85.9
|
|
Biotechnology
|
254.76M
|
50.4
Composite
|
$7.07
|
Valuation
60.8
|
|
ADAG
Adagene Inc.
Biotechnology
|
253.72M
|
53.9
Composite
|
$3.98
|
Profitability
66.8
|
|
Biotechnology
|
252.10M
|
36.8
Composite
|
$6.87
|
Valuation
57.2
|
|
Biotechnology
|
251.21M
|
63.3
Composite
|
$3.77
|
Profitability
77.8
|
|
Biotechnology
|
250.60M
|
51.6
Composite
|
$2.15
|
Efficiency
60.0
|
|
Shell Companies
|
247.02M
|
57.7
Composite
|
$10.81
|
Profitability
73.8
|
|
Biotechnology
|
245.42M
|
55.1
Composite
|
$4.18
|
Profitability
73.7
|
|
Biotechnology
|
244.31M
|
58.0
Composite
|
$4.08
|
Profitability
63.0
|
|
ACIU
AC Immune SA
Biotechnology
|
244.20M
|
44.2
Composite
|
$2.45
|
Valuation
54.4
|
|
Biotechnology
|
243.40M
|
63.2
Composite
|
$73.80
|
Profitability
79.2
|
|
Biotechnology
|
235.40M
|
65.8
Composite
|
$2.54
|
Profitability
78.3
|
|
Shell Companies
|
233.30M
|
55.7
Composite
|
$10.79
|
Profitability
71.1
|
|
Biotechnology
|
231.00M
|
55.5
Composite
|
$4.11
|
Profitability
68.4
|
|
Biotechnology
|
228.30M
|
52.0
Composite
|
$1.48
|
Profitability
68.1
|
|
Biotechnology
|
224.80M
|
50.3
Composite
|
$3.72
|
Profitability
59.2
|
|
Biotechnology
|
221.18M
|
51.2
Composite
|
$1.83
|
Growth
67.0
|
|
Biotechnology
|
219.34M
|
47.2
Composite
|
$1.76
|
Health
58.3
|
|
Biotechnology
|
218.09M
|
49.3
Composite
|
$4.20
|
Efficiency
58.3
|
|
Biotechnology
|
217.31M
|
76.3
Composite
|
$10.98
|
Profitability
85.5
|
|
Biotechnology
|
217.10M
|
42.7
Composite
|
$4.66
|
Profitability
55.1
|
|
Biotechnology
|
216.56M
|
58.0
Composite
|
$12.94
|
Health
65.5
|
|
CLLS
Cellectis S.A.
Biotechnology
|
216.40M
|
55.1
Composite
|
$2.82
|
Profitability
72.5
|
|
CDXS
Codexis, Inc.
Biotechnology
|
215.40M
|
59.5
Composite
|
$2.37
|
Profitability
67.6
|
|
QTTB
Q32 Bio Inc.
Biotechnology
|
214.50M
|
62.5
Composite
|
$12.65
|
Profitability
77.3
|
|
Biotechnology
|
214.00M
|
50.4
Composite
|
$7.23
|
Profitability
71.0
|
|
Shell Companies
|
212.80M
|
53.8
Composite
|
$10.73
|
Growth
77.8
|
|
Biotechnology
|
210.13M
|
50.3
Composite
|
$7.87
|
Profitability
56.5
|
|
Biotechnology
|
204.40M
|
43.3
Composite
|
$9.00
|
Profitability
58.4
|
|
Biotechnology
|
202.50M
|
56.4
Composite
|
$1.88
|
Profitability
68.6
|
|
KRRO
Korro Bio, Inc.
Biotechnology
|
200.47M
|
42.5
Composite
|
$13.90
|
Valuation
53.0
|
|
NKTX
Nkarta, Inc.
Biotechnology
|
199.61M
|
55.6
Composite
|
$2.79
|
Profitability
63.6
|
|
THAR
Tharimmune, Inc.
Biotechnology
|
198.86M
|
55.4
Composite
|
$3.51
|
Valuation
80.2
|
|
Biotechnology
|
194.49M
|
50.4
Composite
|
$4.98
|
Efficiency
60.8
|
|
Biotechnology
|
194.48M
|
49.0
Composite
|
$12.20
|
Growth
56.5
|
|
ALEC
Alector, Inc.
Biotechnology
|
194.29M
|
44.1
Composite
|
$1.83
|
Health
57.9
|
|
IMUX
Immunic, Inc.
Biotechnology
|
193.43M
|
46.0
Composite
|
$14.75
|
Health
51.6
|
|
CGEN
Compugen Ltd.
Biotechnology
|
190.10M
|
72.5
Composite
|
$2.07
|
Profitability
85.7
|
|
Shell Companies
|
186.47M
|
57.5
Composite
|
$11.10
|
Profitability
71.1
|
|
HUMA
Humacyte, Inc.
Biotechnology
|
186.34M
|
46.8
Composite
|
$0.84
|
Growth
55.5
|
|
Biotechnology
|
184.40M
|
36.4
Composite
|
$2.80
|
Efficiency
57.8
|
|
MDWD
MediWound Ltd.
Biotechnology
|
183.02M
|
59.0
Composite
|
$13.96
|
Profitability
72.5
|
|
Biotechnology
|
182.48M
|
58.9
Composite
|
$5.82
|
Profitability
70.7
|
|
Biotechnology
|
180.83M
|
54.3
Composite
|
$2.86
|
Profitability
68.6
|
|
Biotechnology
|
179.36M
|
43.3
Composite
|
$4.44
|
Valuation
55.1
|
|
Biotechnology
|
178.23M
|
47.7
Composite
|
$1.31
|
Valuation
61.2
|
|
Biotechnology
|
175.71M
|
51.6
Composite
|
$7.08
|
Profitability
63.9
|
|
Biotechnology
|
174.00M
|
57.9
Composite
|
$2.16
|
Profitability
78.8
|
|
IPHA
Innate Pharma S.A.
Biotechnology
|
173.31M
|
40.7
Composite
|
$1.81
|
Profitability
46.5
|
|
Biotechnology
|
172.58M
|
46.9
Composite
|
$2.71
|
Profitability
70.2
|
|
Shell Companies
|
170.32M
|
60.4
Composite
|
$10.62
|
Growth
82.5
|
|
Shell Companies
|
169.56M
|
49.0
Composite
|
$10.65
|
Growth
67.1
|
|
Biotechnology
|
163.23M
|
41.9
Composite
|
$2.41
|
Efficiency
57.5
|
|
Biotechnology
|
162.66M
|
49.1
Composite
|
$1.64
|
Valuation
55.9
|
|
Biotechnology
|
159.98M
|
43.3
Composite
|
$14.00
|
Valuation
50.4
|
|
Biotechnology
|
158.80M
|
62.1
Composite
|
$4.01
|
Profitability
79.3
|
|
Biotechnology
|
158.54M
|
55.2
Composite
|
$0.70
|
Profitability
62.0
|
|
Biotechnology
|
154.00M
|
55.0
Composite
|
$8.31
|
Health
62.1
|
|
Biotechnology
|
150.36M
|
52.3
Composite
|
$1.68
|
Growth
62.8
|
|
Biotechnology
|
150.17M
|
50.2
Composite
|
$0.62
|
Profitability
70.0
|
|
Biotechnology
|
148.70M
|
40.8
Composite
|
$1.15
|
Growth
48.9
|
|
ACOG
Alpha Cognition Inc.
Biotechnology
|
147.19M
|
55.4
Composite
|
$6.58
|
Profitability
75.6
|
|
Biotechnology
|
145.40M
|
58.7
Composite
|
$29.08
|
Profitability
78.0
|
|
Biotechnology
|
144.11M
|
39.6
Composite
|
$54.70
|
Valuation
48.6
|
|
Biotechnology
|
143.80M
|
45.6
Composite
|
$3.90
|
Valuation
59.8
|
|
Biotechnology
|
141.09M
|
48.8
Composite
|
$3.95
|
Efficiency
60.1
|
|
ADCT
ADC Therapeutics SA
Biotechnology
|
138.64M
|
49.5
Composite
|
$1.15
|
Profitability
70.0
|
|
GUTS
Fractyl Health, Inc.
Biotechnology
|
136.17M
|
47.3
Composite
|
$0.87
|
Valuation
62.7
|
|
PYXS
Pyxis Oncology, Inc.
Biotechnology
|
134.95M
|
49.7
Composite
|
$2.13
|
Health
56.6
|
|
Biotechnology
|
132.00M
|
60.8
Composite
|
$2.21
|
Profitability
82.3
|
|
GNLX
Genelux Corporation
Biotechnology
|
129.67M
|
43.1
Composite
|
$2.92
|
Valuation
65.6
|
|
Biotechnology
|
129.09M
|
70.3
Composite
|
$0.54
|
Profitability
84.3
|
|
AGEN
Agenus Inc.
Biotechnology
|
126.60M
|
48.0
Composite
|
$3.07
|
Profitability
65.9
|
|
Biotechnology
|
125.93M
|
43.3
Composite
|
$1.99
|
Valuation
63.4
|
|
Biotechnology
|
124.30M
|
54.5
Composite
|
$30.73
|
Growth
70.1
|
|
Biotechnology
|
124.09M
|
60.1
Composite
|
$5.29
|
Profitability
76.7
|
|
PEPG
PepGen Inc.
Biotechnology
|
123.81M
|
53.5
Composite
|
$1.83
|
Health
58.3
|
|
Biotechnology
|
123.70M
|
53.1
Composite
|
$2.02
|
Efficiency
65.0
|
|
Shell Companies
|
121.85M
|
53.6
Composite
|
$11.01
|
Growth
68.0
|
|
FGMC
FG Merger II Corp.
Shell Companies
|
121.39M
|
58.6
Composite
|
$14.89
|
Efficiency
91.0
|
|
Shell Companies
|
115.36M
|
46.4
Composite
|
$10.81
|
Profitability
67.8
|
|
Biotechnology
|
114.24M
|
70.0
Composite
|
$2.65
|
Profitability
83.0
|
|
ENGN
enGene Holdings Inc.
Biotechnology
|
113.21M
|
52.0
Composite
|
$1.69
|
Efficiency
89.1
|
|
Shell Companies
|
109.67M
|
56.8
Composite
|
$17.11
|
Profitability
69.3
|
|
Biotechnology
|
109.40M
|
44.0
Composite
|
$0.92
|
Profitability
51.0
|
|
Shell Companies
|
109.19M
|
50.7
Composite
|
$12.61
|
Valuation
68.6
|
|
Biotechnology
|
102.30M
|
61.6
Composite
|
$3.08
|
Profitability
73.4
|
|
Shell Companies
|
100.17M
|
65.9
Composite
|
$10.45
|
Growth
88.5
|
|
CBUS
Cibus, Inc.
Biotechnology
|
99.20M
|
51.6
Composite
|
$1.30
|
Health
61.2
|
|
PYPD
PolyPid Ltd.
Biotechnology
|
98.36M
|
48.5
Composite
|
$5.13
|
Valuation
56.6
|
|
VANI
Vivani Medical, Inc.
Biotechnology
|
97.45M
|
49.8
Composite
|
$1.13
|
Health
60.3
|
|
Biotechnology
|
96.90M
|
58.5
Composite
|
$5.64
|
Health
62.8
|
|
SEER
Seer, Inc.
Biotechnology
|
96.77M
|
55.9
Composite
|
$1.76
|
Profitability
64.1
|
|
Biotechnology
|
95.77M
|
46.6
Composite
|
$10.68
|
Valuation
62.2
|
|
Shell Companies
|
95.69M
|
45.1
Composite
|
$30.90
|
Valuation
54.3
|
|
Biotechnology
|
95.60M
|
53.4
Composite
|
$10.61
|
Profitability
69.8
|
|
Biotechnology
|
94.20M
|
49.7
Composite
|
$2.76
|
Valuation
51.8
|
|
Biotechnology
|
92.60M
|
46.2
Composite
|
$7.48
|
Profitability
56.7
|
|
Biotechnology
|
92.26M
|
71.0
Composite
|
$1.61
|
Profitability
81.8
|
|
Biotechnology
|
91.30M
|
38.8
Composite
|
$1.11
|
Valuation
58.2
|
|
Shell Companies
|
90.15M
|
38.5
Composite
|
$12.65
|
Profitability
51.9
|
|
Shell Companies
|
89.51M
|
49.2
Composite
|
$10.89
|
Profitability
64.2
|
|
NRXS
Neuraxis, Inc.
Biotechnology
|
88.67M
|
54.8
Composite
|
$7.16
|
Profitability
56.3
|
|
Biotechnology
|
88.50M
|
54.1
Composite
|
$4.93
|
Profitability
73.6
|
|
ICCC
ImmuCell Corporation
Biotechnology
|
88.16M
|
68.5
Composite
|
$9.75
|
Profitability
80.4
|
|
Biotechnology
|
88.03M
|
58.1
Composite
|
$1.28
|
Growth
87.7
|
|
Biotechnology
|
86.80M
|
63.1
Composite
|
$6.25
|
Profitability
84.8
|
|
IBIO
iBio, Inc.
Biotechnology
|
86.44M
|
49.1
Composite
|
$1.74
|
Efficiency
71.0
|
|
ACET
Adicet Bio, Inc.
Biotechnology
|
86.42M
|
46.4
Composite
|
$8.15
|
Profitability
55.7
|
|
Biotechnology
|
85.74M
|
58.3
Composite
|
$4.23
|
Profitability
74.1
|
|
BMEA
Biomea Fusion, Inc.
Biotechnology
|
85.31M
|
49.2
Composite
|
$1.23
|
Health
56.0
|
|
Biotechnology
|
85.20M
|
49.4
Composite
|
$0.90
|
Efficiency
98.6
|
|
Biotechnology
|
85.12M
|
47.7
Composite
|
$1.38
|
Valuation
64.2
|
|
Shell Companies
|
84.88M
|
49.5
Composite
|
$11.27
|
Profitability
55.0
|
|
Shell Companies
|
84.69M
|
54.2
Composite
|
$11.15
|
Growth
100.0
|
|
RLYB
Rallybio Corporation
Biotechnology
|
84.26M
|
55.9
Composite
|
$15.93
|
Profitability
60.5
|
|
Biotechnology
|
82.70M
|
47.3
Composite
|
$1.30
|
Efficiency
54.8
|
|
Shell Companies
|
82.53M
|
59.2
Composite
|
$10.93
|
Growth
77.5
|
|
OKYO
OKYO Pharma Limited
Biotechnology
|
82.39M
|
44.3
Composite
|
$1.57
|
Profitability
68.1
|
|
GOSS
Gossamer Bio, Inc.
Biotechnology
|
82.13M
|
45.5
Composite
|
$0.16
|
Profitability
56.4
|
|
Biotechnology
|
81.20M
|
56.7
Composite
|
$0.43
|
Profitability
70.8
|
|
Biotechnology
|
81.06M
|
44.2
Composite
|
$1.82
|
Efficiency
88.7
|
|
Biotechnology
|
78.91M
|
46.5
Composite
|
$1.85
|
Valuation
58.4
|
|
Shell Companies
|
78.77M
|
34.6
Composite
|
$12.70
|
Valuation
59.6
|
|
Biotechnology
|
78.17M
|
51.7
Composite
|
$0.77
|
Health
65.1
|
|
Biotechnology
|
76.16M
|
44.1
Composite
|
$4.14
|
Health
51.9
|
|
ANVS
Annovis Bio, Inc.
Biotechnology
|
75.30M
|
46.7
Composite
|
$1.74
|
Growth
62.5
|
|
EURKU
Eureka Acquisition Corp
Shell Companies
|
72.60M
|
46.2
Composite
|
$11.59
|
Valuation
62.3
|
|
Biotechnology
|
72.19M
|
48.5
Composite
|
$0.17
|
Profitability
59.0
|
|
Biotechnology
|
71.98M
|
61.1
Composite
|
$19.92
|
Profitability
73.5
|
|
Biotechnology
|
71.83M
|
44.3
Composite
|
$1.16
|
Valuation
56.9
|
|
Biotechnology
|
71.70M
|
61.4
Composite
|
$3.17
|
Profitability
72.6
|
|
XBIT
XBiotech Inc.
Biotechnology
|
70.40M
|
47.6
Composite
|
$2.31
|
Profitability
66.8
|
|
Shell Companies
|
69.82M
|
35.8
Composite
|
$10.94
|
Health
72.3
|
|
Biotechnology
|
69.60M
|
58.4
Composite
|
$1.36
|
Profitability
68.2
|
|
Biotechnology
|
69.45M
|
53.1
Composite
|
$16.40
|
Profitability
61.5
|
|
EXOZ
eXoZymes, Inc.
Biotechnology
|
69.36M
|
50.9
Composite
|
$8.18
|
Efficiency
86.4
|
|
Shell Companies
|
68.23M
|
50.8
Composite
|
$11.05
|
Profitability
59.0
|
|
Biotechnology
|
67.63M
|
51.6
Composite
|
$1.63
|
Efficiency
92.7
|
|
Shell Companies
|
67.18M
|
49.2
Composite
|
$12.20
|
Profitability
54.3
|
|
KALA
KALA BIO, Inc.
Biotechnology
|
67.10M
|
36.2
Composite
|
$3.54
|
Health
52.0
|
|
BYSI
BeyondSpring, Inc.
Biotechnology
|
66.40M
|
54.5
Composite
|
$1.61
|
Profitability
76.5
|
|
CING
Cingulate Inc.
Biotechnology
|
65.58M
|
49.4
Composite
|
$4.94
|
Health
56.4
|
|
MNOV
MediciNova, Inc.
Biotechnology
|
65.00M
|
50.3
Composite
|
$1.30
|
Health
57.3
|
|
Biotechnology
|
63.90M
|
63.9
Composite
|
$6.60
|
Valuation
82.8
|
|
Biotechnology
|
61.03M
|
51.3
Composite
|
$12.25
|
Profitability
71.6
|
|
Biotechnology
|
60.80M
|
52.4
Composite
|
$1.14
|
Valuation
59.5
|
|
EDSA
Edesa Biotech, Inc.
Biotechnology
|
60.55M
|
56.9
Composite
|
$6.81
|
Profitability
70.6
|
|
ENTX
Entera Bio Ltd.
Biotechnology
|
59.56M
|
48.0
Composite
|
$1.48
|
Valuation
59.5
|
|
Shell Companies
|
58.33M
|
52.2
Composite
|
$11.03
|
Growth
84.5
|
|
Biotechnology
|
57.87M
|
51.8
Composite
|
$0.63
|
Efficiency
60.8
|
|
Biotechnology
|
57.37M
|
43.8
Composite
|
$0.53
|
Growth
55.4
|
|
Biotechnology
|
57.25M
|
56.5
Composite
|
$1.15
|
Profitability
71.4
|
|
Biotechnology
|
56.53M
|
47.5
Composite
|
$0.86
|
Efficiency
54.1
|
|
Biotechnology
|
56.21M
|
54.1
Composite
|
$0.52
|
Growth
69.7
|
|
IMMP
Immutep Limited
Biotechnology
|
55.60M
|
49.7
Composite
|
$0.38
|
Profitability
61.5
|
|
Shell Companies
|
55.43M
|
49.9
Composite
|
$11.03
|
Growth
62.4
|
|
Shell Companies
|
55.21M
|
44.7
Composite
|
$11.43
|
Profitability
51.7
|
|
Biotechnology
|
53.86M
|
50.0
Composite
|
$7.29
|
Profitability
56.2
|
|
IBAC
IB Acquisition Corp.
Shell Companies
|
53.59M
|
44.1
Composite
|
$10.70
|
Health
56.6
|
|
Biotechnology
|
53.49M
|
59.9
Composite
|
$8.94
|
Growth
76.3
|
|
Biotechnology
|
52.53M
|
46.5
Composite
|
$0.94
|
Health
60.1
|
|
Biotechnology
|
52.13M
|
52.7
Composite
|
$1.54
|
Profitability
61.8
|
|
Biotechnology
|
51.88M
|
44.3
Composite
|
$0.33
|
Efficiency
59.8
|
|
TIL
Instil Bio, Inc.
Biotechnology
|
50.86M
|
51.4
Composite
|
$7.56
|
Profitability
62.1
|
|
APLM
Apollomics Inc.
Biotechnology
|
50.14M
|
43.4
Composite
|
$20.09
|
Profitability
62.6
|
|
ATHA
Athira Pharma, Inc.
Biotechnology
|
50.13M
|
54.9
Composite
|
$7.66
|
Profitability
70.6
|
|
Shell Companies
|
49.47M
|
56.0
Composite
|
$11.91
|
Valuation
67.6
|
|
LTRN
Lantern Pharma Inc.
Biotechnology
|
49.31M
|
47.7
Composite
|
$3.88
|
Valuation
56.6
|
|
Shell Companies
|
49.23M
|
30.3
Composite
|
$11.68
|
Health
43.5
|
|
Biotechnology
|
48.09M
|
48.8
Composite
|
$1.93
|
Growth
71.0
|
|
VERU
Veru Inc.
Biotechnology
|
47.50M
|
56.8
Composite
|
$2.96
|
Profitability
72.3
|
|
Shell Companies
|
46.63M
|
46.6
Composite
|
$10.88
|
Profitability
61.4
|
|
ATYR
aTyr Pharma, Inc.
Biotechnology
|
46.10M
|
42.4
Composite
|
$0.47
|
Valuation
61.4
|
|
Biotechnology
|
45.29M
|
57.6
Composite
|
$1.92
|
Growth
73.6
|
|
Shell Companies
|
45.15M
|
34.4
Composite
|
$11.57
|
Health
53.5
|
|
MGX
Metagenomi, Inc.
Biotechnology
|
44.80M
|
54.3
Composite
|
$1.19
|
Profitability
74.0
|
|
Shell Companies
|
43.89M
|
46.3
Composite
|
$11.71
|
Valuation
60.3
|
|
Shell Companies
|
43.64M
|
41.1
Composite
|
$12.20
|
Profitability
46.5
|
|
Shell Companies
|
41.39M
|
50.0
Composite
|
$11.33
|
Profitability
54.3
|
|
Biotechnology
|
41.12M
|
47.9
Composite
|
$9.82
|
Profitability
68.1
|
|
RNXT
RenovoRx, Inc.
Biotechnology
|
41.05M
|
52.6
Composite
|
$0.91
|
Growth
60.0
|
|
Biotechnology
|
40.20M
|
43.6
Composite
|
$0.93
|
Profitability
63.3
|
|
Biotechnology
|
40.10M
|
37.0
Composite
|
$1.30
|
Efficiency
54.1
|
|
Shell Companies
|
39.33M
|
31.5
Composite
|
$12.55
|
Profitability
42.3
|
|
CRVO
CervoMed Inc.
Biotechnology
|
39.26M
|
51.0
Composite
|
$4.13
|
Profitability
70.7
|
|
Shell Companies
|
38.71M
|
62.4
Composite
|
$11.02
|
Profitability
71.3
|
|
Biotechnology
|
38.70M
|
58.4
Composite
|
$2.26
|
Profitability
77.2
|
|
INMB
INmune Bio Inc.
Biotechnology
|
38.55M
|
44.8
Composite
|
$1.43
|
Valuation
62.2
|
|
Shell Companies
|
38.13M
|
29.7
Composite
|
$13.27
|
Valuation
47.5
|
|
NTRB
Nutriband Inc.
Biotechnology
|
37.80M
|
44.8
Composite
|
$3.11
|
Profitability
64.3
|
|
Shell Companies
|
37.05M
|
39.2
Composite
|
$13.45
|
Health
56.0
|
|
SNPX
Synaptogenix, Inc.
Biotechnology
|
36.76M
|
0.0
Composite
|
$24.55
|
No pillar score
-
|
|
Biotechnology
|
35.21M
|
43.4
Composite
|
$5.65
|
Health
57.9
|
|
Shell Companies
|
34.52M
|
55.4
Composite
|
$5.80
|
Profitability
65.2
|
|
ABVC
ABVC Biopharma, Inc.
Biotechnology
|
34.30M
|
55.6
Composite
|
$1.31
|
Profitability
72.0
|
|
Shell Companies
|
32.80M
|
48.7
Composite
|
$11.98
|
Valuation
61.1
|
|
Biotechnology
|
32.30M
|
42.1
Composite
|
$1.03
|
Valuation
56.5
|
|
BOLD
Boundless Bio, Inc.
Biotechnology
|
32.12M
|
48.4
Composite
|
$1.40
|
Efficiency
69.4
|
|
Biotechnology
|
31.60M
|
44.8
Composite
|
$3.47
|
Valuation
56.8
|
|
Biotechnology
|
31.12M
|
43.4
Composite
|
$23.30
|
Valuation
56.5
|
|
Biotechnology
|
30.70M
|
51.8
Composite
|
$2.05
|
Health
55.6
|
|
Biotechnology
|
30.35M
|
39.9
Composite
|
$0.97
|
Efficiency
62.4
|
|
Shell Companies
|
29.15M
|
30.8
Composite
|
$7.33
|
Valuation
50.9
|
|
Shell Companies
|
28.95M
|
32.5
Composite
|
$0.58
|
Valuation
57.9
|
|
Shell Companies
|
28.62M
|
34.8
Composite
|
$12.50
|
Valuation
67.0
|
|
Biotechnology
|
28.60M
|
50.9
Composite
|
$0.78
|
Health
56.6
|
|
NNVC
NanoViricides, Inc.
Biotechnology
|
28.60M
|
59.9
Composite
|
$1.32
|
Efficiency
97.5
|
|
EVAX
Evaxion Biotech A/S
Biotechnology
|
28.52M
|
61.1
Composite
|
$3.42
|
Profitability
72.6
|
|
Biotechnology
|
28.51M
|
44.6
Composite
|
$0.70
|
Profitability
59.3
|
|
Biotechnology
|
28.35M
|
40.3
Composite
|
$1.89
|
Valuation
57.4
|
|
FGEN
FibroGen, Inc
Biotechnology
|
27.90M
|
56.3
Composite
|
$7.21
|
Profitability
71.7
|
|
Biotechnology
|
27.89M
|
37.9
Composite
|
$0.79
|
Profitability
51.3
|
|
Shell Companies
|
27.52M
|
39.9
Composite
|
$9.19
|
Efficiency
53.6
|
|
Biotechnology
|
27.40M
|
48.6
Composite
|
$3.98
|
Profitability
57.0
|
|
IGC
IGC Pharma, Inc.
Biotechnology
|
26.70M
|
53.4
Composite
|
$0.27
|
Profitability
66.8
|
|
Biotechnology
|
26.30M
|
45.3
Composite
|
$0.64
|
Valuation
51.9
|
|
Biotechnology
|
26.20M
|
42.0
Composite
|
$3.01
|
Growth
65.1
|
|
NKGN
NKGen Biotech, Inc.
Biotechnology
|
26.12M
|
41.6
Composite
|
$0.06
|
Valuation
71.5
|
|
MEIP
MEI Pharma, Inc.
Biotechnology
|
25.70M
|
0.0
Composite
|
$3.07
|
No pillar score
-
|
|
Shell Companies
|
25.46M
|
57.7
Composite
|
$10.89
|
Health
65.5
|
|
LGVN
Longeveron Inc.
Biotechnology
|
24.93M
|
41.5
Composite
|
$0.80
|
Efficiency
60.4
|
|
Biotechnology
|
24.90M
|
39.9
Composite
|
$0.71
|
Valuation
55.9
|
|
PLRZ
Polyrizon Ltd.
Biotechnology
|
24.69M
|
52.8
Composite
|
$13.19
|
Profitability
68.6
|
|
Biotechnology
|
24.00M
|
57.2
Composite
|
$4.44
|
Profitability
78.0
|
|
Biotechnology
|
22.80M
|
54.1
Composite
|
$1.37
|
Profitability
69.7
|
|
Shell Companies
|
22.51M
|
38.8
Composite
|
$9.72
|
Profitability
54.2
|
|
CELU
Celularity Inc.
Biotechnology
|
21.94M
|
43.3
Composite
|
$0.76
|
Profitability
66.2
|
|
PLUR
Pluri Inc.
Biotechnology
|
21.80M
|
43.7
Composite
|
$2.02
|
Efficiency
67.6
|
|
Biotechnology
|
21.66M
|
47.8
Composite
|
$0.65
|
Growth
57.8
|
|
Biotechnology
|
21.64M
|
46.9
Composite
|
$1.32
|
Growth
67.1
|
|
Biotechnology
|
21.04M
|
44.6
Composite
|
$1.10
|
Valuation
53.9
|
|
Biotechnology
|
20.90M
|
42.3
Composite
|
$11.77
|
Valuation
56.5
|
|
Biotechnology
|
20.50M
|
40.0
Composite
|
$2.57
|
Health
53.5
|
|
LPCN
Lipocine Inc.
Biotechnology
|
19.20M
|
49.0
Composite
|
$2.29
|
Profitability
65.7
|
|
Biotechnology
|
18.51M
|
42.9
Composite
|
$1.25
|
Health
50.4
|
|
GTBP
GT Biopharma, Inc.
Biotechnology
|
18.50M
|
49.1
Composite
|
$0.49
|
Efficiency
99.4
|
|
PASG
Passage Bio, Inc.
Biotechnology
|
18.35M
|
49.5
Composite
|
$5.72
|
Health
57.6
|
|
Biotechnology
|
18.01M
|
54.0
Composite
|
$0.54
|
Profitability
65.0
|
|
Biotechnology
|
17.65M
|
56.8
Composite
|
$1.01
|
Profitability
61.0
|
|
AEON
AEON Biopharma, Inc.
Biotechnology
|
17.57M
|
35.8
Composite
|
$0.69
|
Profitability
44.5
|
|
XCUR
Exicure, Inc.
Biotechnology
|
17.50M
|
43.7
Composite
|
$2.74
|
Profitability
57.5
|
|
Biotechnology
|
17.07M
|
45.6
Composite
|
$0.37
|
Efficiency
68.0
|
|
CRIS
Curis, Inc.
Biotechnology
|
16.70M
|
50.9
Composite
|
$0.43
|
Profitability
56.0
|
|
MLEC
Moolec Science SA
Biotechnology
|
16.62M
|
44.2
Composite
|
$7.99
|
Profitability
72.0
|
|
Biotechnology
|
16.60M
|
42.7
Composite
|
$3.12
|
Health
58.6
|
|
Biotechnology
|
16.15M
|
57.5
Composite
|
$0.40
|
Profitability
73.9
|
|
Biotechnology
|
15.80M
|
45.7
Composite
|
$1.83
|
Health
56.8
|
|
Biotechnology
|
15.60M
|
56.3
Composite
|
$0.57
|
Profitability
70.5
|
|
Biotechnology
|
15.12M
|
39.2
Composite
|
$0.93
|
Efficiency
61.9
|
|
Biotechnology
|
14.50M
|
44.6
Composite
|
$0.58
|
Profitability
50.1
|
|
BLRX
BioLineRx Ltd.
Biotechnology
|
14.10M
|
58.7
Composite
|
$3.24
|
Profitability
67.7
|
|
INAB
IN8bio, Inc.
Biotechnology
|
14.08M
|
56.2
Composite
|
$1.46
|
Profitability
62.3
|
|
Biotechnology
|
14.04M
|
46.7
Composite
|
$0.50
|
Health
59.5
|
|
HOOK
HOOKIPA Pharma Inc.
Biotechnology
|
13.86M
|
58.0
Composite
|
$1.15
|
Profitability
74.7
|
|
Biotechnology
|
13.80M
|
40.5
Composite
|
$1.00
|
Growth
51.4
|
|
Biotechnology
|
13.66M
|
59.1
Composite
|
$3.22
|
Profitability
71.8
|
|
TRAW
Traws Pharma, Inc.
Biotechnology
|
13.51M
|
51.0
Composite
|
$0.89
|
Profitability
67.0
|
|
BIVI
BioVie Inc.
Biotechnology
|
13.30M
|
50.9
Composite
|
$1.94
|
Profitability
65.6
|
|
Biotechnology
|
12.85M
|
49.7
Composite
|
$11.79
|
Growth
61.0
|
|
Biotechnology
|
12.78M
|
50.1
Composite
|
$1.08
|
Profitability
65.4
|
|
Biotechnology
|
12.54M
|
57.2
Composite
|
$3.24
|
Growth
74.4
|
|
Biotechnology
|
12.20M
|
51.7
Composite
|
$1.05
|
Growth
68.2
|
|
CALC
CalciMedica, Inc.
Biotechnology
|
11.93M
|
37.0
Composite
|
$0.78
|
Valuation
46.7
|
|
RENB
Renovaro Inc.
Biotechnology
|
11.60M
|
0.0
Composite
|
$0.32
|
No pillar score
-
|
|
Biotechnology
|
11.60M
|
46.7
Composite
|
$0.25
|
Health
52.2
|
|
BCDA
BioCardia, Inc.
Biotechnology
|
11.00M
|
38.5
Composite
|
$0.97
|
Valuation
56.5
|
|
Biotechnology
|
10.90M
|
52.5
Composite
|
$2.47
|
Profitability
70.4
|
|
Biotechnology
|
10.87M
|
44.6
Composite
|
$1.51
|
Profitability
57.5
|
|
Biotechnology
|
10.64M
|
49.0
Composite
|
$3.94
|
Profitability
57.3
|
|
Biotechnology
|
10.40M
|
41.0
Composite
|
$0.41
|
Valuation
57.5
|
|
Biotechnology
|
9.99M
|
40.2
Composite
|
$0.23
|
Valuation
52.9
|
|
Biotechnology
|
9.83M
|
52.4
Composite
|
$0.79
|
Profitability
59.5
|
|
Biotechnology
|
9.53M
|
43.5
Composite
|
$1.33
|
Profitability
63.5
|
|
IMRN
Immuron Limited
Biotechnology
|
9.40M
|
49.0
Composite
|
$1.15
|
Profitability
68.7
|
|
Biotechnology
|
9.34M
|
47.4
Composite
|
$4.41
|
Health
66.0
|
|
KAPA
Kairos Pharma, Ltd.
Biotechnology
|
9.23M
|
58.3
Composite
|
$0.43
|
Efficiency
97.2
|
|
Biotechnology
|
9.15M
|
47.0
Composite
|
$0.70
|
Valuation
62.0
|
|
Biotechnology
|
9.12M
|
36.8
Composite
|
$3.18
|
Valuation
44.8
|
|
Biotechnology
|
8.61M
|
50.9
Composite
|
$0.90
|
Profitability
60.6
|
|
Biotechnology
|
8.39M
|
43.1
Composite
|
$0.36
|
Efficiency
68.4
|
|
HCWB
HCW Biologics Inc.
Biotechnology
|
8.31M
|
43.4
Composite
|
$1.16
|
Efficiency
67.6
|
|
Biotechnology
|
8.20M
|
60.6
Composite
|
$0.77
|
Profitability
79.1
|
|
SYBX
Synlogic, Inc.
Biotechnology
|
8.19M
|
44.0
Composite
|
$0.72
|
Valuation
56.9
|
|
Biotechnology
|
8.17M
|
37.8
Composite
|
$6.45
|
Valuation
44.0
|
|
MTVA
MetaVia Inc.
Biotechnology
|
8.11M
|
49.4
Composite
|
$1.57
|
Health
63.6
|
|
Biotechnology
|
7.71M
|
46.8
Composite
|
$4.01
|
Profitability
54.4
|
|
IMNN
Imunon, Inc.
Biotechnology
|
7.60M
|
48.1
Composite
|
$1.80
|
Health
55.0
|
|
NCNA
NuCana plc
Biotechnology
|
7.60M
|
56.1
Composite
|
$1.83
|
Efficiency
86.3
|
|
Biotechnology
|
7.29M
|
58.5
Composite
|
$1.50
|
Growth
76.0
|
|
Biotechnology
|
7.11M
|
40.4
Composite
|
$3.10
|
Profitability
61.3
|
|
Biotechnology
|
7.10M
|
42.6
Composite
|
$1.93
|
Valuation
50.7
|
|
Biotechnology
|
6.99M
|
49.9
Composite
|
$0.83
|
Profitability
60.3
|
|
Biotechnology
|
6.87M
|
39.1
Composite
|
$5.89
|
Efficiency
53.2
|
|
Biotechnology
|
6.70M
|
61.4
Composite
|
$2.94
|
Profitability
77.0
|
|
Biotechnology
|
6.55M
|
41.4
Composite
|
$3.06
|
Valuation
51.3
|
|
Biotechnology
|
6.46M
|
53.4
Composite
|
$1.42
|
Growth
70.8
|
|
NXTC
NextCure, Inc.
Biotechnology
|
6.32M
|
49.2
Composite
|
$1.75
|
Health
54.8
|
|
PPBT
Purple Biotech Ltd.
Biotechnology
|
6.27M
|
45.1
Composite
|
$1.70
|
Profitability
58.0
|
|
Biotechnology
|
6.26M
|
41.0
Composite
|
$4.28
|
Valuation
55.2
|
|
ELAB
PMGC Holdings Inc.
Biotechnology
|
6.13M
|
48.5
Composite
|
$1.35
|
Health
57.5
|
|
BCAB
BioAtla, Inc.
Biotechnology
|
6.00M
|
43.2
Composite
|
$3.62
|
Efficiency
57.6
|
|
Biotechnology
|
5.90M
|
46.9
Composite
|
$4.75
|
Health
59.9
|
|
Shell Companies
|
5.87M
|
55.1
Composite
|
$0.38
|
Growth
82.5
|
|
Biotechnology
|
5.83M
|
43.9
Composite
|
$1.97
|
Efficiency
67.2
|
|
Biotechnology
|
5.81M
|
40.2
Composite
|
$2.55
|
Growth
55.7
|
|
GNPX
Genprex, Inc.
Biotechnology
|
5.80M
|
37.7
Composite
|
$0.55
|
Growth
59.3
|
|
Biotechnology
|
5.80M
|
49.1
Composite
|
$2.08
|
Efficiency
93.6
|
|
SNGX
Soligenix, Inc.
Biotechnology
|
5.80M
|
43.5
Composite
|
$0.39
|
Health
56.5
|
|
Biotechnology
|
5.72M
|
60.2
Composite
|
$2.70
|
Profitability
77.4
|
|
PULM
Pulmatrix, Inc.
Biotechnology
|
5.62M
|
44.9
Composite
|
$1.54
|
Health
50.6
|
|
EVGN
Evogene Ltd.
Biotechnology
|
5.52M
|
52.0
Composite
|
$0.50
|
Profitability
74.9
|
|
Biotechnology
|
5.10M
|
46.1
Composite
|
$2.16
|
Efficiency
59.4
|
|
Biotechnology
|
4.95M
|
51.8
Composite
|
$1.23
|
Growth
65.0
|
|
Biotechnology
|
4.90M
|
48.5
Composite
|
$0.34
|
Growth
55.3
|
|
MBIO
Mustang Bio, Inc.
Biotechnology
|
4.90M
|
54.1
Composite
|
$0.67
|
Profitability
72.5
|
|
Biotechnology
|
4.90M
|
42.5
Composite
|
$1.33
|
Valuation
52.8
|
|
Biotechnology
|
4.75M
|
42.7
Composite
|
$5.00
|
Valuation
47.3
|
|
ALZN
Alzamend Neuro, Inc.
Biotechnology
|
4.64M
|
54.9
Composite
|
$1.37
|
Efficiency
96.5
|
|
GOVX
GeoVax Labs, Inc.
Biotechnology
|
4.58M
|
39.0
Composite
|
$1.32
|
Valuation
44.5
|
|
PHGE
BiomX Inc.
Biotechnology
|
4.57M
|
42.6
Composite
|
$0.45
|
Profitability
61.7
|
|
Biotechnology
|
4.43M
|
41.5
Composite
|
$2.98
|
Health
46.8
|
|
Biotechnology
|
4.36M
|
48.0
Composite
|
$1.69
|
Profitability
56.4
|
|
Biotechnology
|
4.35M
|
45.6
Composite
|
$0.13
|
Profitability
59.9
|
|
FBLG
FibroBiologics, Inc.
Biotechnology
|
4.35M
|
49.8
Composite
|
$0.81
|
Valuation
55.8
|
|
Biotechnology
|
4.29M
|
45.0
Composite
|
$1.23
|
Valuation
53.0
|
|
Biotechnology
|
4.17M
|
49.5
Composite
|
$0.08
|
Profitability
54.8
|
|
Biotechnology
|
4.10M
|
39.9
Composite
|
$1.05
|
Health
59.4
|
|
Biotechnology
|
4.01M
|
43.1
Composite
|
$0.27
|
Valuation
53.5
|
|
Biotechnology
|
4.00M
|
46.8
Composite
|
$0.63
|
Growth
55.0
|
|
SPRC
SciSparc Ltd.
Biotechnology
|
4.00M
|
38.4
Composite
|
$6.97
|
Health
41.5
|
|
AZTR
Azitra Inc
Biotechnology
|
3.72M
|
31.3
Composite
|
$0.23
|
Efficiency
56.8
|
|
Biotechnology
|
3.72M
|
57.0
Composite
|
$8.28
|
Efficiency
94.1
|
|
Biotechnology
|
3.70M
|
60.2
Composite
|
$0.56
|
Growth
68.9
|
|
ONCO
Onconetix, Inc.
Biotechnology
|
3.50M
|
45.7
Composite
|
$0.95
|
Health
61.1
|
|
GRI
GRI Bio, Inc.
Biotechnology
|
3.33M
|
46.5
Composite
|
$1.87
|
Profitability
60.4
|
|
Biotechnology
|
3.29M
|
42.9
Composite
|
$0.16
|
Health
57.4
|
|
Biotechnology
|
3.25M
|
42.9
Composite
|
$0.16
|
Valuation
61.1
|
|
VCNX
Vaccinex, Inc.
Biotechnology
|
2.81M
|
37.0
Composite
|
$1.10
|
Profitability
48.3
|
|
OGEN
Oragenics Inc.
Biotechnology
|
2.60M
|
55.9
Composite
|
$0.58
|
Growth
62.9
|
|
Shell Companies
|
2.38M
|
57.6
Composite
|
$2.34
|
Growth
60.7
|
|
Biotechnology
|
2.25M
|
43.1
Composite
|
$3.01
|
Health
56.6
|
|
Biotechnology
|
2.15M
|
51.2
Composite
|
$0.02
|
Profitability
57.8
|
|
Biotechnology
|
1.62M
|
43.9
Composite
|
$0.17
|
Valuation
58.5
|
|
JAGX
Jaguar Health, Inc.
Biotechnology
|
1.57M
|
38.4
Composite
|
$2.61
|
Profitability
52.4
|
|
Biotechnology
|
1.28M
|
44.0
Composite
|
$0.45
|
Growth
54.7
|
|
Biotechnology
|
1.15M
|
50.0
Composite
|
$0.29
|
Health
58.1
|
|
Biotechnology
|
1.13M
|
44.4
Composite
|
$2.70
|
Growth
66.7
|
|
Biotechnology
|
1.05M
|
50.6
Composite
|
$0.30
|
Profitability
60.0
|
|
Biotechnology
|
1.01M
|
44.4
Composite
|
$0.57
|
Efficiency
58.9
|
|
Biotechnology
|
891,300
|
55.4
Composite
|
$0.01
|
Profitability
67.6
|
|
Biotechnology
|
631,573
|
44.6
Composite
|
$0.01
|
Efficiency
92.6
|
|
Biotechnology
|
516,620
|
42.8
Composite
|
$0.03
|
Valuation
54.8
|
|
Biotechnology
|
497,436
|
50.0
Composite
|
$2.06
|
Growth
58.4
|
|
IOBT
IO Biotech, Inc.
Biotechnology
|
467,667
|
51.4
Composite
|
$0.01
|
Health
66.2
|
|
Biotechnology
|
441,572
|
40.7
Composite
|
$0.05
|
Growth
58.9
|
|
Biotechnology
|
337,087
|
37.8
Composite
|
$0.02
|
Growth
50.2
|
|
Shell Companies
|
301,262
|
33.3
Composite
|
$0.05
|
Efficiency
84.2
|
|
Biotechnology
|
161,729
|
50.5
Composite
|
$0.08
|
Profitability
56.7
|
|
Biotechnology
|
69,709
|
37.4
Composite
|
$0.00
|
Profitability
46.3
|
|
VINC
Vincerx Pharma, Inc.
Biotechnology
|
65,428
|
42.8
Composite
|
$0.01
|
Efficiency
55.1
|
|
ADTX
Aditxt, Inc.
Biotechnology
|
15,666
|
34.6
Composite
|
$0.04
|
Health
55.8
|
|
Biotechnology
|
12,074
|
46.2
Composite
|
$0.00
|
Profitability
54.3
|
|
Biotechnology
|
941
|
37.6
Composite
|
$0.00
|
Efficiency
58.4
|
|
Biotechnology
|
621
|
37.0
Composite
|
$0.01
|
Health
42.0
|
|
ATNFW
180 Life Sciences Corp.
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
TSVT
2seventy bio, Inc.
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
CSLMF
6816
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
ETNB
89bio, Inc.
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
53.5
Composite
|
$11.03
|
Health
66.0
|
|
Shell Companies
|
-
|
46.0
Composite
|
$10.66
|
Health
64.3
|
|
Biotechnology
|
-
|
61.3
Composite
|
-
|
Profitability
72.7
|
|
ABPWW
Abpro Holdings, Inc.
Biotechnology
|
-
|
40.2
Composite
|
$0.01
|
Profitability
46.3
|
|
SLRN
ACELYRIN, INC.
Biotechnology
|
-
|
36.0
Composite
|
-
|
Health
56.8
|
|
Biotechnology
|
-
|
58.7
Composite
|
-
|
Health
65.9
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
53.7
Composite
|
-
|
Profitability
72.8
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
AFMD
Affimed N.V.
Biotechnology
|
-
|
42.5
Composite
|
$0.18
|
Health
63.5
|
|
Shell Companies
|
-
|
48.5
Composite
|
$0.22
|
Health
52.5
|
|
Shell Companies
|
-
|
50.4
Composite
|
$11.49
|
Profitability
54.3
|
|
Shell Companies
|
-
|
50.5
Composite
|
-
|
Growth
100.0
|
|
Shell Companies
|
-
|
50.5
Composite
|
-
|
Growth
100.0
|
|
Shell Companies
|
-
|
39.8
Composite
|
$35.90
|
Profitability
47.2
|
|
Shell Companies
|
-
|
0.0
Composite
|
$19.26
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
$18.15
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
$0.04
|
No pillar score
-
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
28.8
Composite
|
$13.50
|
Health
45.4
|
|
ALDFU
Aldel Financial II Inc.
Shell Companies
|
-
|
60.4
Composite
|
$10.81
|
Growth
77.9
|
|
Shell Companies
|
-
|
58.9
Composite
|
$0.34
|
Growth
77.9
|
|
ALLK
Allakos Inc.
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
ALVR
AlloVir, Inc.
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
52.8
Composite
|
$1.02
|
Efficiency
69.5
|
|
Shell Companies
|
-
|
49.5
Composite
|
-
|
Efficiency
62.6
|
|
Shell Companies
|
-
|
52.4
Composite
|
-
|
Health
62.7
|
|
Shell Companies
|
-
|
51.1
Composite
|
-
|
Efficiency
62.6
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
30.9
Composite
|
-
|
Profitability
46.6
|
|
Shell Companies
|
-
|
32.1
Composite
|
$4.50
|
Profitability
46.6
|
|
Shell Companies
|
-
|
34.6
Composite
|
$12.01
|
Profitability
49.8
|
|
Shell Companies
|
-
|
55.7
Composite
|
$10.83
|
Growth
80.6
|
|
Biotechnology
|
-
|
48.0
Composite
|
$0.10
|
Profitability
53.1
|
|
Biotechnology
|
-
|
44.8
Composite
|
$1.71
|
Health
57.1
|
|
APXIU
APx Acquisition Corp. I
Shell Companies
|
-
|
39.7
Composite
|
-
|
Profitability
69.0
|
|
Shell Companies
|
-
|
26.3
Composite
|
-
|
Efficiency
48.6
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
26.2
Composite
|
$12.79
|
Health
30.2
|
|
Shell Companies
|
-
|
23.5
Composite
|
-
|
Health
30.2
|
|
Shell Companies
|
-
|
27.7
Composite
|
-
|
Profitability
42.4
|
|
Shell Companies
|
-
|
27.8
Composite
|
-
|
Profitability
42.7
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
51.9
Composite
|
-
|
Health
68.8
|
|
Shell Companies
|
-
|
37.4
Composite
|
-
|
Health
43.7
|
|
Shell Companies
|
-
|
37.4
Composite
|
-
|
Health
43.7
|
|
BAYAU
Bayview Acquisition Corp
Shell Companies
|
-
|
41.2
Composite
|
$12.11
|
Efficiency
53.2
|
|
BGNE
BeiGene, Ltd.
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
36.0
Composite
|
-
|
Health
46.1
|
|
Biotechnology
|
-
|
41.8
Composite
|
$0.03
|
Growth
77.6
|
|
Shell Companies
|
-
|
52.4
Composite
|
$12.11
|
Health
57.3
|
|
Shell Companies
|
-
|
65.8
Composite
|
$11.00
|
Growth
100.0
|
|
BLEUU
bleuacacia ltd
Shell Companies
|
-
|
32.9
Composite
|
-
|
Efficiency
44.8
|
|
BLEU
bleuacacia ltd
Shell Companies
|
-
|
32.9
Composite
|
-
|
Efficiency
44.8
|
|
BLEUW
bleuacacia ltd Warrants
Shell Companies
|
-
|
33.4
Composite
|
-
|
Efficiency
44.8
|
|
BLUE
bluebird bio, Inc.
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
60.0
Composite
|
$10.90
|
Growth
85.2
|
|
Shell Companies
|
-
|
32.8
Composite
|
$0.00
|
Efficiency
72.9
|
|
BOWNU
Bowen Acquisition Corp
Shell Companies
|
-
|
35.8
Composite
|
-
|
Efficiency
50.6
|
|
Biotechnology
|
-
|
46.3
Composite
|
$0.00
|
Growth
64.9
|
|
Shell Companies
|
-
|
0.0
Composite
|
$11.70
|
No pillar score
-
|
|
Shell Companies
|
-
|
41.3
Composite
|
$12.00
|
Health
50.5
|
|
Shell Companies
|
-
|
45.4
Composite
|
-
|
Health
52.6
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
36.3
Composite
|
$0.09
|
Profitability
48.6
|
|
Shell Companies
|
-
|
36.3
Composite
|
$15.95
|
Profitability
48.6
|
|
Shell Companies
|
-
|
44.7
Composite
|
-
|
Growth
66.2
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
39.6
Composite
|
$0.03
|
Efficiency
67.2
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
$11.69
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
$180.56
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
$11.75
|
No pillar score
-
|
|
Shell Companies
|
-
|
51.6
Composite
|
$11.17
|
Growth
85.3
|
|
CELUW
Celularity Inc.
Biotechnology
|
-
|
44.8
Composite
|
$0.01
|
Profitability
66.7
|
|
Shell Companies
|
-
|
46.9
Composite
|
$10.91
|
Efficiency
65.0
|
|
Biotechnology
|
-
|
40.8
Composite
|
$0.00
|
Efficiency
92.6
|
|
Shell Companies
|
-
|
39.8
Composite
|
$11.28
|
Health
50.6
|
|
CFFSU
CF Acquisition Corp. VII
Shell Companies
|
-
|
39.8
Composite
|
$11.18
|
Health
50.6
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
45.9
Composite
|
$10.80
|
Growth
77.6
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
CMRX
Chimerix, Inc.
Biotechnology
|
-
|
46.9
Composite
|
-
|
Health
66.7
|
|
Shell Companies
|
-
|
52.9
Composite
|
$10.90
|
Growth
58.1
|
|
Biotechnology
|
-
|
45.5
Composite
|
$221.38
|
Growth
49.0
|
|
CINGW
Cingulate Inc. Warrants
Biotechnology
|
-
|
47.0
Composite
|
$0.06
|
Health
56.4
|
|
CLRC
ClimateRock
Shell Companies
|
-
|
0.0
Composite
|
$12.00
|
No pillar score
-
|
|
CLRCU
ClimateRock
Shell Companies
|
-
|
0.0
Composite
|
$12.00
|
No pillar score
-
|
|
CLRCW
ClimateRock Warrant
Shell Companies
|
-
|
0.0
Composite
|
$0.03
|
No pillar score
-
|
|
Shell Companies
|
-
|
63.0
Composite
|
$11.25
|
Growth
84.6
|
|
Shell Companies
|
-
|
63.0
Composite
|
$0.11
|
Growth
84.6
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
39.1
Composite
|
$0.01
|
Profitability
53.5
|
|
Biotechnology
|
-
|
0.0
Composite
|
$2.72
|
No pillar score
-
|
|
CYBN
Cybin Inc.
Biotechnology
|
-
|
56.6
Composite
|
$7.61
|
Efficiency
73.4
|
|
Biotechnology
|
-
|
56.0
Composite
|
-
|
Profitability
79.2
|
|
Biotechnology
|
-
|
44.0
Composite
|
-
|
Profitability
56.6
|
|
Shell Companies
|
-
|
0.0
Composite
|
$11.43
|
No pillar score
-
|
|
Shell Companies
|
-
|
31.1
Composite
|
$11.84
|
Efficiency
43.9
|
|
Shell Companies
|
-
|
0.0
Composite
|
$0.04
|
No pillar score
-
|
|
Biotechnology
|
-
|
42.6
Composite
|
$0.02
|
Growth
58.0
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
26.4
Composite
|
-
|
Health
32.9
|
|
Shell Companies
|
-
|
26.4
Composite
|
-
|
Health
32.9
|
|
Shell Companies
|
-
|
26.4
Composite
|
-
|
Health
32.9
|
|
Shell Companies
|
-
|
19.5
Composite
|
-
|
Efficiency
32.9
|
|
Shell Companies
|
-
|
19.3
Composite
|
-
|
Efficiency
32.9
|
|
DUETU
DUET Acquisition Corp.
Shell Companies
|
-
|
38.6
Composite
|
-
|
Health
47.3
|
|
Shell Companies
|
-
|
38.6
Composite
|
-
|
Health
47.3
|
|
Shell Companies
|
-
|
38.6
Composite
|
-
|
Health
47.3
|
|
DYNXU
Dynamix Corporation
Shell Companies
|
-
|
0.0
Composite
|
$10.89
|
No pillar score
-
|
|
DYNX
Dynamix Corporation
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
$0.78
|
No pillar score
-
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
$12.80
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
$11.00
|
No pillar score
-
|
|
Shell Companies
|
-
|
45.9
Composite
|
-
|
Health
51.9
|
|
Biotechnology
|
-
|
56.0
Composite
|
$2.23
|
Efficiency
90.5
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
EPIX
ESSA Pharma Inc.
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
41.6
Composite
|
$0.14
|
Profitability
59.8
|
|
EYEN
Eyenovia, Inc.
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
50.3
Composite
|
$11.99
|
Efficiency
60.5
|
|
FGMCU
FG Merger II Corp.
Shell Companies
|
-
|
54.3
Composite
|
$11.79
|
Efficiency
90.8
|
|
Shell Companies
|
-
|
30.9
Composite
|
$0.16
|
Health
37.3
|
|
Shell Companies
|
-
|
33.7
Composite
|
-
|
Health
52.5
|
|
Shell Companies
|
-
|
33.7
Composite
|
-
|
Health
52.5
|
|
Shell Companies
|
-
|
0.0
Composite
|
$0.05
|
No pillar score
-
|
|
Shell Companies
|
-
|
31.2
Composite
|
$11.01
|
Health
37.9
|
|
FICVW
Frontier Investment Corp
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
$12.00
|
No pillar score
-
|
|
FHLTU
Future Health ESG Corp.
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
FHLTW
Future Health ESG Corp.
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
64.3
Composite
|
$11.19
|
Growth
77.5
|
|
Shell Companies
|
-
|
24.3
Composite
|
$12.00
|
Health
41.5
|
|
Shell Companies
|
-
|
24.3
Composite
|
$0.03
|
Health
41.5
|
|
Shell Companies
|
-
|
25.2
Composite
|
$12.02
|
Health
41.5
|
|
GBIO
Generation Bio Co.
Biotechnology
|
-
|
54.1
Composite
|
$5.34
|
Valuation
62.9
|
|
GNFT
GENFIT S.A.
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
GOVXW
GeoVax Labs, Inc.
Biotechnology
|
-
|
39.7
Composite
|
-
|
Growth
44.8
|
|
Shell Companies
|
-
|
56.0
Composite
|
$9.94
|
Growth
69.6
|
|
Shell Companies
|
-
|
0.0
Composite
|
$11.50
|
No pillar score
-
|
|
Shell Companies
|
-
|
40.1
Composite
|
$0.00
|
Health
64.1
|
|
Shell Companies
|
-
|
0.0
Composite
|
$10.82
|
No pillar score
-
|
|
Shell Companies
|
-
|
51.3
Composite
|
$11.00
|
Growth
95.8
|
|
Shell Companies
|
-
|
0.0
Composite
|
$6.56
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
$6.50
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
$0.04
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
GLYC
GlycoMimetics, Inc.
Biotechnology
|
-
|
45.6
Composite
|
-
|
Health
66.4
|
|
Shell Companies
|
-
|
37.1
Composite
|
$0.02
|
Profitability
47.8
|
|
Shell Companies
|
-
|
25.9
Composite
|
$10.72
|
Health
32.1
|
|
Shell Companies
|
-
|
54.4
Composite
|
$10.88
|
Profitability
63.7
|
|
Shell Companies
|
-
|
54.4
Composite
|
$0.18
|
Profitability
63.7
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
$15.52
|
No pillar score
-
|
|
HONDU
HCM II Acquisition Corp.
Shell Companies
|
-
|
36.3
Composite
|
-
|
Profitability
40.1
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
$13.90
|
No pillar score
-
|
|
Shell Companies
|
-
|
53.8
Composite
|
$10.77
|
Growth
100.0
|
|
Shell Companies
|
-
|
0.0
Composite
|
$0.18
|
No pillar score
-
|
|
HHGCU
HHG Capital Corporation
Shell Companies
|
-
|
50.8
Composite
|
-
|
Profitability
59.2
|
|
Shell Companies
|
-
|
50.8
Composite
|
-
|
Profitability
59.2
|
|
Shell Companies
|
-
|
51.9
Composite
|
-
|
Profitability
60.5
|
|
HLVX
HilleVax, Inc.
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
33.6
Composite
|
$0.04
|
Profitability
44.8
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
48.1
Composite
|
$5.00
|
Growth
84.9
|
|
Shell Companies
|
-
|
24.9
Composite
|
-
|
Profitability
32.9
|
|
Shell Companies
|
-
|
24.5
Composite
|
-
|
Profitability
31.3
|
|
HUMAW
Humacyte, Inc.
Biotechnology
|
-
|
42.1
Composite
|
$0.11
|
Health
49.0
|
|
IMAB
I-MAB
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
IKNA
Ikena Oncology, Inc.
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
IMTXW
Immatics N.V.
Biotechnology
|
-
|
47.9
Composite
|
-
|
Profitability
63.1
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
37.8
Composite
|
-
|
Profitability
55.5
|
|
Shell Companies
|
-
|
37.8
Composite
|
$2.31
|
Profitability
55.5
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
INZY
Inozyme Pharma, Inc.
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
45.3
Composite
|
$10.40
|
Health
54.1
|
|
Shell Companies
|
-
|
43.0
Composite
|
$11.49
|
Health
54.1
|
|
Shell Companies
|
-
|
43.0
Composite
|
$0.05
|
Health
54.1
|
|
Shell Companies
|
-
|
0.0
Composite
|
$12.00
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
$11.86
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
$0.02
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
$5.51
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
$9.50
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
$0.10
|
No pillar score
-
|
|
ISRLU
Israel Acquisitions Corp
Shell Companies
|
-
|
31.8
Composite
|
$11.02
|
Health
49.7
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
IXQWF
IX Acquisition Corp.
Shell Companies
|
-
|
22.2
Composite
|
-
|
Health
27.2
|
|
Biotechnology
|
-
|
43.4
Composite
|
$0.02
|
Health
59.5
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
JVSAU
JVSPAC Acquisition Corp.
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
46.1
Composite
|
$12.30
|
Profitability
54.3
|
|
Shell Companies
|
-
|
46.1
Composite
|
$0.06
|
Profitability
54.3
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
53.7
Composite
|
$0.10
|
Growth
66.7
|
|
KRON
Kronos Bio, Inc.
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
58.9
Composite
|
$0.63
|
Profitability
68.8
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
LEXXW
Lexaria Bioscience Corp.
Biotechnology
|
-
|
44.1
Composite
|
$0.00
|
Health
50.8
|
|
Biotechnology
|
-
|
40.8
Composite
|
$0.02
|
Profitability
44.9
|
|
Shell Companies
|
-
|
19.4
Composite
|
$36.05
|
Growth
25.8
|
|
Shell Companies
|
-
|
61.4
Composite
|
$30.28
|
Growth
71.8
|
|
Shell Companies
|
-
|
16.5
Composite
|
-
|
Growth
24.4
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
MRUS
Merus N.V.
Biotechnology
|
-
|
54.2
Composite
|
$90.00
|
Profitability
62.6
|
|
Shell Companies
|
-
|
20.9
Composite
|
$11.50
|
Efficiency
30.6
|
|
Shell Companies
|
-
|
20.6
Composite
|
$11.89
|
Health
29.5
|
|
Shell Companies
|
-
|
29.3
Composite
|
$0.02
|
Health
36.1
|
|
Biotechnology
|
-
|
46.2
Composite
|
$0.03
|
Profitability
69.7
|
|
MCAA
Mountain
Shell Companies
|
-
|
42.7
Composite
|
-
|
Efficiency
50.7
|
|
MCAAU
Mountain
Shell Companies
|
-
|
42.7
Composite
|
-
|
Efficiency
50.7
|
|
Shell Companies
|
-
|
42.7
Composite
|
-
|
Efficiency
50.7
|
|
Shell Companies
|
-
|
24.1
Composite
|
$10.92
|
Profitability
41.5
|
|
MURA
Mural Oncology plc
Biotechnology
|
-
|
51.1
Composite
|
-
|
Profitability
60.0
|
|
Shell Companies
|
-
|
45.5
Composite
|
-
|
Health
56.4
|
|
Shell Companies
|
-
|
45.5
Composite
|
-
|
Health
56.4
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
33.7
Composite
|
$0.21
|
Profitability
52.1
|
|
Shell Companies
|
-
|
25.7
Composite
|
-
|
Health
38.8
|
|
Shell Companies
|
-
|
25.7
Composite
|
-
|
Health
38.8
|
|
Shell Companies
|
-
|
27.5
Composite
|
-
|
Health
38.8
|
|
Biotechnology
|
-
|
45.0
Composite
|
$18.70
|
Health
56.8
|
|
Shell Companies
|
-
|
44.2
Composite
|
$0.08
|
Health
52.2
|
|
Shell Companies
|
-
|
46.4
Composite
|
$12.99
|
Health
52.6
|
|
Shell Companies
|
-
|
63.8
Composite
|
$10.65
|
Growth
85.2
|
|
Biotechnology
|
-
|
41.8
Composite
|
$0.03
|
Health
42.9
|
|
NLSPW
NLS Pharmaceutics Ltd.
Biotechnology
|
-
|
0.0
Composite
|
$0.02
|
No pillar score
-
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
42.3
Composite
|
$0.01
|
Profitability
50.2
|
|
NTRBW
Nutriband Inc. Warrant
Biotechnology
|
-
|
43.5
Composite
|
$1.21
|
Profitability
61.7
|
|
Shell Companies
|
-
|
43.0
Composite
|
$12.07
|
Health
46.3
|
|
Shell Companies
|
-
|
63.2
Composite
|
$10.73
|
Growth
77.9
|
|
Biotechnology
|
-
|
0.0
Composite
|
$0.14
|
No pillar score
-
|
|
OABIW
OmniAb, Inc.
Biotechnology
|
-
|
54.1
Composite
|
$0.09
|
Profitability
69.0
|
|
Biotechnology
|
-
|
46.2
Composite
|
-
|
Profitability
53.8
|
|
OPT
Opthea Limited
Biotechnology
|
-
|
33.7
Composite
|
-
|
Health
47.1
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
51.1
Composite
|
$0.01
|
Profitability
66.4
|
|
Shell Companies
|
-
|
39.5
Composite
|
-
|
Valuation
100.0
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
4.5
Composite
|
-
|
Profitability
18.0
|
|
Shell Companies
|
-
|
35.6
Composite
|
$12.00
|
Efficiency
84.4
|
|
Shell Companies
|
-
|
35.2
Composite
|
-
|
Efficiency
81.8
|
|
Shell Companies
|
-
|
35.2
Composite
|
$11.32
|
Efficiency
81.8
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
65.4
Composite
|
$10.88
|
Growth
100.0
|
|
Shell Companies
|
-
|
29.9
Composite
|
$11.00
|
Efficiency
42.6
|
|
PRTG
Portage Biotech Inc.
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
43.0
Composite
|
$0.01
|
Growth
51.5
|
|
Biotechnology
|
-
|
42.6
Composite
|
$0.02
|
Profitability
77.9
|
|
Shell Companies
|
-
|
32.6
Composite
|
-
|
Health
47.5
|
|
Shell Companies
|
-
|
44.7
Composite
|
-
|
Profitability
47.5
|
|
Shell Companies
|
-
|
31.0
Composite
|
-
|
Health
44.4
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
38.2
Composite
|
$11.70
|
Health
54.6
|
|
Shell Companies
|
-
|
60.1
Composite
|
$10.84
|
Growth
82.5
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
50.7
Composite
|
-
|
Profitability
72.1
|
|
Biotechnology
|
-
|
43.4
Composite
|
$0.01
|
Health
64.7
|
|
Biotechnology
|
-
|
36.5
Composite
|
-
|
Health
50.8
|
|
Biotechnology
|
-
|
44.1
Composite
|
$1.88
|
Efficiency
61.7
|
|
Shell Companies
|
-
|
62.8
Composite
|
$11.06
|
Profitability
82.3
|
|
RFAC
RF Acquisition Corp.
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
RFACU
RF Acquisition Corp.
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
53.7
Composite
|
$13.00
|
Growth
100.0
|
|
Shell Companies
|
-
|
53.9
Composite
|
$7.60
|
Profitability
69.5
|
|
Biotechnology
|
-
|
55.9
Composite
|
$0.04
|
Growth
66.6
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
44.3
Composite
|
$0.03
|
Profitability
61.4
|
|
SIMAU
SIM Acquisition Corp I
Shell Companies
|
-
|
50.6
Composite
|
$11.17
|
Profitability
63.2
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
40.5
Composite
|
$13.43
|
Health
57.6
|
|
Shell Companies
|
-
|
40.5
Composite
|
$0.22
|
Health
57.6
|
|
Shell Companies
|
-
|
39.6
Composite
|
$12.70
|
Health
47.0
|
|
Shell Companies
|
-
|
37.9
Composite
|
-
|
Health
47.0
|
|
Shell Companies
|
-
|
41.7
Composite
|
-
|
Profitability
50.0
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
59.4
Composite
|
$10.82
|
Growth
100.0
|
|
SRZNW
Surrozen, Inc. Warrant
Biotechnology
|
-
|
40.7
Composite
|
$0.02
|
Profitability
45.0
|
|
Shell Companies
|
-
|
53.1
Composite
|
$10.73
|
Growth
77.5
|
|
Biotechnology
|
-
|
0.0
Composite
|
$0.50
|
No pillar score
-
|
|
Biotechnology
|
-
|
51.8
Composite
|
$0.01
|
Profitability
64.9
|
|
Biotechnology
|
-
|
0.0
Composite
|
$3.39
|
No pillar score
-
|
|
Biotechnology
|
-
|
42.4
Composite
|
-
|
Health
66.8
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
TRML
Tourmaline Bio, Inc.
Biotechnology
|
-
|
44.1
Composite
|
-
|
Health
65.2
|
|
Shell Companies
|
-
|
49.1
Composite
|
$11.99
|
Growth
77.8
|
|
TRVN
Trevena, Inc.
Biotechnology
|
-
|
38.7
Composite
|
$0.01
|
Profitability
53.8
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
VMCAU
Valuence Merger Corp. I
Shell Companies
|
-
|
46.1
Composite
|
$11.37
|
Profitability
65.7
|
|
Shell Companies
|
-
|
0.0
Composite
|
$11.74
|
No pillar score
-
|
|
VMCAW
Valuence Merger Corp. I
Shell Companies
|
-
|
0.0
Composite
|
$0.05
|
No pillar score
-
|
|
VRNA
Verona Pharma plc
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
45.3
Composite
|
$11.21
|
Growth
72.5
|
|
Biotechnology
|
-
|
44.7
Composite
|
-
|
Efficiency
61.2
|
|
Shell Companies
|
-
|
58.2
Composite
|
$14.50
|
Profitability
66.4
|
|
Shell Companies
|
-
|
30.2
Composite
|
$7.50
|
Profitability
44.6
|
|
Shell Companies
|
-
|
29.1
Composite
|
$10.00
|
Profitability
41.0
|
|
Shell Companies
|
-
|
59.6
Composite
|
$28.38
|
Growth
84.8
|
|
Shell Companies
|
-
|
26.4
Composite
|
$11.32
|
Profitability
38.0
|
|
Shell Companies
|
-
|
26.4
Composite
|
-
|
Profitability
38.0
|
|
Biotechnology
|
-
|
65.8
Composite
|
$25.49
|
Profitability
81.9
|
|
Biotechnology
|
-
|
65.6
Composite
|
$25.43
|
Profitability
81.9
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
42.6
Composite
|
$10.89
|
Profitability
57.0
|
|
Shell Companies
|
-
|
23.8
Composite
|
$10.01
|
Profitability
43.4
|
|
Shell Companies
|
-
|
26.7
Composite
|
$2.00
|
Profitability
47.4
|
|
Shell Companies
|
-
|
23.8
Composite
|
-
|
Profitability
43.4
|
Try a broader company name, ticker, sector, or industry keyword.
This framework combines industry-specific diagnostics, moat context, and peer benchmarks so each signal stays grounded in how this business model actually compounds.
We group pre-commercial biotech and similarly early-stage businesses into a separate framework because revenue, margins, and near-term profitability are often the wrong lens. The money-flow engine starts with cash on hand, then follows operating expense, R&D intensity, operating cash burn, financing inflows, and estimated runway.
That same logic carries into the broader StatsAlpha(TM) framework. The trade-off ledger for pre-revenue biotech is intentionally sparse in the current implementation: profitability is disabled, safety focuses on liquidity and cash position, and the code explicitly flags the need for future runway and burn-specific calculators. That is a feature, not a gap in judgment. The framework avoids pretending these businesses can be compared like mature cash generators.
On the moat and valuation side, biotech currently inherits broader corporate tools where needed, but the fair-value defaults also acknowledge the category's binary nature and note that a probability-of-success layer would be preferable to a smooth-growth DCF. In practice, this profile should be read as a disciplined way to track funding durability and upside optionality, not as a shortcut to certainty. This framework is for informational purposes only, not investment advice.
Each layer answers a different question: where value is created, what protects it, and how execution compares with the rest of the coverage set.
Benchmarks and narrative cues are meant to clarify what the framework is seeing in the data. They are not investment advice.
Coverage starts with the companies that actually operate inside this business model, so peer comparisons stay relevant instead of generic.
The Biotech / Pre-Revenue layer isolates the cash-flow mechanics, capital demands, and operating risk that matter most for this industry.
We then layer in Corporate Default, pillar ranges, and peer leaders to show what strong execution looks like relative to the broader cohort.